var docs;if (!docs) docs =[]; docs["83"]={"8300":"<p><b>Title</b> Methotrexate / Dipyrone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dipyrone may enhance the adverse/toxic effect of Methotrexate. Methotrexate may enhance the adverse/toxic effect of Dipyrone. Specifically, the risk for agranulocytosis and pancytopenia may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of dipyrone with methotrexate</p> \n<p><b>Discussion</b> Use of dipyrone is independently associated with a significant risk for agranulocytosis and pancytopenia, which are serious and potentially life-threatening toxicities. Alhough specific risk factors for this reaction are not well known, concurrent use of dipyrone with drugs that are known to suppress the bone marrow, such as methotrexate, should be avoided in order to minimize the likelihood that such a combination may increase the risk for agranulocytosis and/or pancytopenia.<sup>1</sup><br><br>Dipyrone may also alter the pharmacokinetics of methotrexate. Although the pharmacokinetics of methotrexate have not been specifically studied with the concomitant use of dipyrone, other nonsteroidal anti-inflammatory agents (NSAIDs) have been studied in this context. Indomethacin and tolmetin have been reported to increase the AUC of methotrexate from 19% to 140% in pediatric patients.<sup>2</sup> Etodolac is reported to increase methotrexate half-life by 38% without any change in AUC,<sup>3</sup> and ibuprofen may decrease methotrexate clearance by 40% to 50%.<sup>4,5</sup> Some NSAIDs may decrease renal excretion of methotrexate by inhibiting renal transport proteins<sup>6,7,8</sup> and/or decreasing renal perfusion. In contrast, other reports conclude that ibuprofen, indomethacin, and several other NSAIDs do not significantly affect methotrexate pharmacokinetics.<sup>9,10,11,12,13,14,15,16</sup><br><br>Regardless of pharmacokinetic changes, several other NSAIDs not independently associated with hematologic toxicities have been associated with the development of methotrexate toxicity (neutropenia, thrombocytopenia, kidney failure) as soon as a day after NSAID initiation in methotrexate-stable patients.<sup>17,18,19,20,21,22</sup> In addition, some NSAIDs may have additive toxicities with methotrexate (e.g., indomethacin - renal toxicity).<br><br>Due to the risk of additive severe hematologic toxicities coupled with the potential for increased methotrexate blood levels and toxicities, according to product labeling, the combination of dipyrone and methotrexate must be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Anador</i> (dipyrone) [Summary of Product Characteristics]. Itapeceria da Serra, Sao Paulo, Brazil: Boehringer Ingelheim Brazil Chemistry and Farm Ltda, 2013.</p>\n<p>2. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate-nonsteroidal anti-inflammatory drug interaction in children with arthritis. <i>J Rheumatol</i>. 1990;17:1469-1473. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2273487\">[PubMed 2273487]</a>]</p>\n<p>3. Anaya JM, Fabre D, Bressolle F, et al. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. <i>J Rheumatol</i>. 1994;21:203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8182625\">[PubMed 8182625]</a></p>\n<p>4. Tracy TS, Jones DR, Hall SK, Brater DC, Bradley JD, Krohn K. The effect of NSAIDs on methotrexate disposition in patients with rheumatoid arthritis. <i>Clin Pharmacol Ther</i>. 1990;47:138 [Abstract 54].</p>\n<p>5. Tracy TS, Krohn K, Jones DR ,Bradley JD, Hall SD, Brater DC. The effects of salicylate, ibuprofen, and naproxen on the disposition of metotrexate in patients with rheumatoid arthritis. <i>Eur J Clin Pharmacol</i>. 1992;42:121-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618240\">[PubMed 1618240]</a></p>\n<p>6. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. <i>J Pharmacol Exp Ther</i>. 2007;320(1):229-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005917\">[PubMed 17005917]</a></p>\n<p>7. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. <i>J Pharmacol Exp Ther</i>. 2004;309(1):226-234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14722319\">[PubMed 14722319]</a></p>\n<p>8. Takeda M, Khamdang S, Narikawa S. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. <i>J Pharmacol Exp Ther</i>. 2002;302(2):666-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12130730\">[PubMed 12130730]</a></p>\n<p>9. Karin A, Tolbert D, Piergies A, et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin. <i>Arthritis Rheum</i>. 1998;41(Suppl 9):S315. [Abstract]</p>\n<p>10. Iqbal MP, Baig JA, Ali AA,Niazi SK, Mehboobali N, Hussain MA. The effects of nonsteroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. <i>Biopharm Drug Dispos</i>. 1998;19:163-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9569999\">[PubMed 9569999]</a></p>\n<p>11. Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. <i>J Rheumatol</i>. 1990;17:1008-1010. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2213774\">[PubMed 2213774]</a></p>\n<p>12. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam, and flurbiprofen in patients with rheumatoid arthritis. <i>Br J Clin Pharmac</i>. 1994;37:453-456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8054251\">[PubMed 8054251]</a></p>\n<p>13. Christophidis N, Dawson TM, Angelis P, et al. A double-blind, randomized, placebo controlled pharmacokinetic and clinical study of the interaction of ketoprofen and naproxen with methotrexate in rheumatoid arthritis. <i>Arthritis Rheum</i>. 1994; 37(Suppl 9):S252. [Abstract] </p>\n<p>14. Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. <i>Clin Pharmacol Ther</i>. 1990;47:540-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2328562\">[PubMed 2328562]</a></p>\n<p>15. Combe B, Edno L, Lafforgue P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. <i>Br J Rheumatol</i>. 1995;34:421-428. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7788170\">[PubMed 7788170]</a></p>\n<p>16. Huebner G, Sander D, Degner FL, Turck D, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. <i>J Rheumatol</i>. 1997;24:845-851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9150070\">[PubMed 9150070]</a></p>\n<p>17. Frenia ML, Long KS. Methotrexate and nonsteroidal anti-inflammatory drug interaction. <i>Ann Pharmacother</i>. 1992;26:234-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1554938\">[PubMed 1554938]</a></p>\n<p>18. Cassano W. Serious methotrexate toxicity caused by interaction with ibuprofen. <i>Am J Ped Hematol/Oncol</i>. 1989;11:481-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2618985\">[PubMed 2618985]</a></p>\n<p>19. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. <i>Lancet</i>. 1986;1(8475):256-258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2868265\">[PubMed 2868265]</a></p>\n<p>20. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. <i>Lancet</i>. 1986;1(8494):1390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2872507\">[PubMed 2872507]</a></p>\n<p>21. Adams JD, Hunter G. Drug interaction in psoriasis. <i>Aust J Dermatol</i>. 1976;17:39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1022213\">[PubMed 1022213]</a></p>\n<p>22. Mayall B, Poggi G, Parkin JD. Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. <i>Med J Aust</i>. 1991;155:480-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1921820\">[PubMed 1921820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8301":"<p><b>Title</b> Myelosuppressive Agents / Dipyrone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dipyrone may enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of dipyrone with any myelosuppressive agent.</p>\n<div>\n <p><b>Myelosuppressive Agents Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Aldesleukin, Alemtuzumab, Altretamine, Amsacrine, Arsenic Trioxide, AzaCITIDine, Belinostat, Belotecan, Bendamustine, Bevacizumab, Bexarotene (Systemic), Blinatumomab, Bortezomib, Bosutinib, Busulfan, Cabazitaxel, Capecitabine, CarBAMazepine, Carbimazole, CARBOplatin, Carfilzomib, Carmustine, Chlorambucil, Chloramphenicol (Ophthalmic), Chloramphenicol (Systemic), CISplatin, Cladribine, Clofarabine, Copanlisib, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, Daratumumab, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, Dexrazoxane, Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Edetate CALCIUM Disodium, EpiRUBicin, EriBULin, Etoposide, Etoposide Phosphate, Everolimus, Floxuridine, Flucytosine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Inotuzumab Ozogamicin, Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Ixazomib, Lenalidomide, Linezolid, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, MethIMAzole, Methotrexate, Midostaurin, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Nilotinib, Niraparib, Obinutuzumab, Olaparib, Olaratumab, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Peginterferon Alfa-2a, Peginterferon Alfa-2b, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PONATinib, Procarbazine, Propylthiouracil, Radium Ra 223 Dichloride, Radotinib, Raltitrexed, Ribociclib, RiTUXimab, RomiDEPsin, Rucaparib, Ruxolitinib, Sirolimus, SORAfenib, Streptozocin, Tacrolimus (Systemic), Tedizolid, Tegafur, Temozolomide, Temsirolimus, Teniposide, Thalidomide, Thioguanine, Thiotepa, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Trifluridine and Tipiracil, Venetoclax, VinBLAStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zidovudine, Ziv-Aflibercept (Systemic)</p>\n</div> \n<p><b>Discussion</b> Use of dipyrone is independently associated with a significant risk for agranulocytosis and pancytopenia, which are serious and potentially life-threatening toxicities. Although specific risk factors for this reaction are not well known, concurrent use of dipyrone with drugs that are known to suppress the bone marrow should be avoided in order to minimize the likelihood that such a combination may increase the risk for agranulocytosis and/or pancytopenia.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Anador</i> (dipyrone) [Summary of Product Characteristics]. Itapeceria da Serra, Sao Paulo, Brazil: Boehringer Ingelheim Brazil Chemistry and Farm Ltda, 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8302":"<p><b>Title</b> Sofosbuvir / Modafinil</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling considers this a potential drug interaction to avoid while the U.S. prescribing information does not.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Modafinil may decrease the serum concentration of Sofosbuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of modafinil and sofosbuvir is not recommended in the Canadian labeling, although evidence for this recommendation is very limited. There is no recommendation to avoid this drug combination in the U.S. prescribing information.</p> \n<p><b>Discussion</b> The U.S. and Canadian prescribing information for sofosbuvir recommend avoiding concomitant use with agents that induce intestinal P-glycoprotein (P-gp) due to the potential for diminished sofosbuvir exposure and effects.<sup>1,2</sup> Rifabutin, rifapentine, and oxcarbazepine are all listed as agents potentially interacting via this mechanism; specific P-gp inducing properties of these agents have not been well characterized in published literature, although all of these agents induce CYP-450 enzymes, all are closely related to established P-gp inducers (eg, rifampin), and rifabutin and rifapentine induction of P-gp is supported by some in vitro data.<sup>3</sup> <br><br>The Canadian product information also lists modafinil as an additional agent that has potential P-gp inducing abilities. While no reports of the induction of P-gp by modafinil have been published, there is evidence that modafinil induces CYP450 3A4<sup>4</sup> and that entities that induce CYP450 3A commonly also induce P-gp.<sup>5,6</sup> However, not all CYP450 3A inducers are always P-gp inducers<sup>7</sup>, and very limited in vitro data suggest modafinil does not induce P-gp.<sup>8</sup> U.S. labeling does not mention modafinil as a potential drug interaction with sofosbuvir.<br><br>Sofosbuvir is a P-gp substrate, but to date, no significant interactions with P-gp inducers in humans have been characterized. The maximum concentration (Cmax) and AUC of sofosbuvir (400 mg single dose) increased by roughly 2.5- and 4.5-fold, respectively, when coadministered with the P-gp inhibitor cyclosporine (600 mg single dose).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sovaldi</i> (sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc., December 2013.</p>\n<p>2. <i>Sovaldi</i> (sofosbuvir) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada, Inc., December 2013. </p>\n<p>3. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6366-6369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24060875\">[PubMed 24060875]</a></p>\n<p>4. <i>Provigil</i> (modafinil) [prescribing information]. Frazer, PA: Cephalon, Inc., March 2008.</p>\n<p>5. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. <i>Mol Pharmacol</i>. 1996;49(2):311-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8632764\">[PubMed 8632764]</a></p>\n<p>6. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. <i>J Pharmacol Exp Ther</i>. 2002;303(1):323-332. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12235267\">[PubMed 12235267]</a></p>\n<p>7. Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. <i>Mol Pharm</i>. 2009;6(6):1766-1774. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19839641\">[PubMed 19839641]</a></p>\n<p>8. Zhu HJ, Wang JS, Donovan JL, et al. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transport P-glycoprotein. <i>Eur J Pharmacol</i>. 2008;578(2-3):148-158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17963743\">[PubMed 17963743]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8303":"<p><b>Title</b> Phenytoin / Miconazole (Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Miconazole (Oral) may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased serum phenytoin concentrations and phenytoin toxicity if these agents are used in combination.</p> \n<p><b>Discussion</b> Although oral miconazole is generally considered nonabsorbed, the prescribing information for miconazole does warn that systemic drug interactions are possible, with an emphasis on CYP2C9- and CYP3A-metabolized drugs, and a specific caution concerning concurrent phenytoin.<sup>1</sup> The prescribing information for phenytoin also lists miconazole as a medication likely to interact with phenytoin.<sup>2</sup><br> <br>A case report describes a 51-year-old male who experienced phenytoin intoxication and supratherapeutic serum phenytoin concentrations following the initiation of intravenous miconazole.<sup>3</sup> There are no reports describing an interaction between phenytoin and oral miconazole.<br><br>The likely mechanism for this reported interaction is miconazole-mediated inhibition of the CYP2C9 and 2C19 metabolism of phenytoin. Miconazole has been shown to be a highly potent inhibitor of CYP2C9 and CYP2C19.<sup>4</sup> However, in vivo concentrations are unlikely to reach the stated inhibitory concentrations with standard use of oral miconazole in most patients, as only 3% of patients had measurable plasma concentrations of miconazole with recommended use of the oral buccal tablet.<sup>1,5</sup> This, along with the lack of studies involving concurrent use of oral miconazole and phenytoin in patients, makes the clinical significance of this potential interaction unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Oravig</i> (miconazole). [prescribing information] Cary, NC: Praelia Pharmaceuticals, Inc; August 2012.</p>\n<p>2. <i>Dilantin</i> (phenytoin). [prescribing information] New York, NY: Pfizer; March 2014.</p>\n<p>3. Rolan PE, Somogyi AA, Drew MJ, Cobain WG, South D, Bochner F. Phenytoin intoxication during treatment with parenteral miconazole. <i>Br Med J (Clin Res Ed)</i>. 1983;287(6407):1760. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6416579\">[PubMed 6416579]</a></p>\n<p>4. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. <i>Biol Pharm Bull</i>. 2005;28(9):1805-1808. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141567\">[PubMed 16141567]</a></p>\n<p>5. Cardot JM, Chaumont C, Dubray C, Costantini D, Aiache JM. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. <i>Br J Clin Pharmacol</i>. 2004;58(4):345-351. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15373926\">[PubMed 15373926]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8304":"<p><b>Title</b> MetFORMIN / Vandetanib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vandetanib may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to metformin closely when used with vandetanib, particularly when initiating therapy with vandetanib. Monitor specifically for evidence of increased metformin effects and/or toxicity.</p> \n<p><b>Discussion</b> The metformin AUC and maximum serum concentration (Cmax) were an average of 74% and 50% higher, respectively, when given with vandetanib in a study of 13 volunteers who received single doses of metformin (1000 mg) alone or 3 hours after a single dose of vandetanib (800 mg).<sup>1</sup> The clinical significance of this purported interaction is unclear.<br><br>The specific mechanism for this interaction is likely vandetanib-mediated inhibition of metformin efflux by OCT2 (organic cation transporter 2) and/or MATE (multidrug and toxin extrusion) transporters.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Caprelsa</i> (vandetanib) [Prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, March 2014.</p>\n<p>2. Shen H, Yang Z, Zhao W, Zhang Y, Rodrigues AD. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. <i>Drug Metab Dispos</i>. 2013;41(12):2095-2103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24026623\">[PubMed 24026623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8305":"<p><b>Title</b> Digoxin / Vandetanib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vandetanib may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to digoxin closely when used with vandetanib, particularly when initiating therapy with vandetanib. Monitor specifically for evidence of increased digoxin effects and/or toxicity.</p> \n<p><b>Discussion</b> The digoxin AUC and maximum serum concentration (Cmax) were an average of 23% and 29% higher, respectively, when given with vandetanib in a study of 14 volunteers who received single doses of digoxin (0.25 mg) alone or together with a single dose of vandetanib (300 mg).<sup>1</sup> The clinical significance of this purported interaction is unclear.<br><br>The specific mechanism for this interaction is likely vandetanib-mediated inhibition of digoxin efflux by the drug transporter p-glycoprotein (P-gp).<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Caprelsa</i> (vandetanib) [Prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, March 2014.</p>\n<p>2. Jovelet C, Benard J, Forestier F, Farinotti R, Bidart JM, Gil S. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. <i>Eur J Pharm Sci</i>. 2012;46(5):484-491. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22484209\">[PubMed 22484209]</a></p>\n<p>3. Mi Y, Lou L. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. <i>Br J Cancer</i>. 2007;97(7):934-940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17912240\">[PubMed 17912240]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8306":"<p><b>Title</b> RifAXIMin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of RifAXIMin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased incidence of rifaximin-related adverse effects when receiving both rifaximin and cyclosporine. In addition, one consequence of this interaction may be an increased likelihood that rifaximin would alter the metabolism of other drugs subject to intestinal and/or hepatic drug metabolism. Patients with underlying hepatic dysfunction and/or gastrointestinal disease may be at a higher risk for a clinically significant interaction.</p> \n<p><b>Discussion</b> Concurrent use of rifaximin and cyclosporine was associated with an average 83-fold increase in rifaximin maximum serum concentration (Cmax) and an average 124-fold increase in the rifaximin AUC in a study of healthy volunteers who received single doses of both cyclosporine (600 mg) and rifaximin (550 mg).<sup>1</sup><br><br>The clinical significance of this interaction is not clear, particularly considering that very little rifaximin is usually absorbed. Such an increase in rifaximin concentration may increase rifaximin toxicities or increase the likelihood that rifaximin may alter the metabolism of other medications. While in vitro studies demonstrate some potential impact of rifaximin on drug-metabolizing enzymes, its low serum concentrations following administration to otherwise healthy individuals has made such an interaction considered clinically unlikely. For example, concurrent use with oral midazolam (as a marker of CYP3A activity) demonstrated only a 4% to 9% decrease in midazolam AUC, suggesting a clinically insignificant induction of CYP3A.<sup>1</sup> With substantial increases in rifaximin concentration, a greater magnitude effect on CYP3A (and possibly other enzymes) may be observed. Additionally, 10 to 20-fold increase in rifaximin AUC has been observed in patients classified as Child-Pugh A, B, and C compared to healthy volunteers using 550 mg twice daily, indicating that this population are at an even higher risk for increased rifaximin exposure and a possibly clinically significant interaction.<sup>1</sup><br><br>The mechanism most likely responsible for this interaction is P-glycoprotein inhibition by cyclosporine, leading to increased rifaximin absorption.<sup>1</sup> Cyclosporine inhibition of other transporters (eg, SLCOs/OATPs, BCRP) or CYP3A4 may also play a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Xifaxan (rifaximin) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8307":"<p><b>Title</b> RifAXIMin / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased incidence of rifaximin-related adverse effects when receiving both rifaximin and a potent P-glycoprotein inhibitor such as cyclosporine. In addition, one consequence of this interaction may be an increased likelihood that rifaximin would alter the metabolism of other drugs subject to intestinal and/or hepatic drug metabolism. Patients with underlying hepatic dysfunction and/or gastrointestinal disease may be at a higher risk for a clinically significant interaction.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> Concurrent use of rifaximin and the P-glycoprotein inhibitor cyclosporine was associated with an average 83-fold increase in rifaximin maximum serum concentration (Cmax) and an average 124-fold increase in the rifaximin AUC in a study of healthy volunteers who received single doses of both cyclosporine (600 mg) and rifaximin (550 mg).<sup>1</sup><br><br>The clinical significance of this interaction is not clear, particularly considering that very little rifaximin is usually absorbed. Such an increase in rifaximin concentration may lead to increased toxicities or increase the likelihood that rifaximin may alter the metabolism of other medications. While in vitro studies demonstrate some potential impact of rifaximin on drug-metabolizing enzymes, its low serum concentrations following administration to otherwise healthy individuals has made such an interaction considered clinically unlikely. For example, concurrent use with oral midazolam (as a marker of CYP3A activity) demonstrated only a 4% to 9% decrease in midazolam AUC, suggesting a clinically insignificant induction of CYP3A.<sup>1</sup> With substantial increases in rifaximin concentration, a greater magnitude effect on CYP3A (and possibly other enzymes) may be observed. Additionally, 10 to 20-fold increase in rifaximin AUC has been observed in patients classified as Child-Pugh A, B, and C compared to healthy volunteers using 550 mg twice daily, indicating that this population are at an even higher risk for increased rifaximin exposure and a possibly clinically significant interaction.<sup>1</sup><br><br>The mechanism most likely responsible for this interaction is P-glycoprotein inhibition by cyclosporine, leading to increased rifaximin absorption.<sup>1</sup> Cyclosporine inhibition of other transporters (eg, SLCOs/OATPs, BCRP) or CYP3A4 may also play a role.<sup>1</sup> The effect of P-gp inhibitors that do not inhibit additional transporters and/or CYP3A4 on rifaximin exposure is unknown, but may be less than what was observed with cyclosporine coadministration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xifaxan (rifaximin) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8308":"<p><b>Title</b> Clindamycin (Topical) / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Erythromycin (Systemic) may diminish the therapeutic effect of Clindamycin (Topical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of systemic erythromycin and topical clindamycin.</p> \n<p><b>Discussion</b> In vitro studies have demonstrated antagonism between erythromycin and lincomycin whereby strains of <i>Staphylococcus</i> spp. and <i>Streptococcus pyogenes</i> that are resistant to erythromycin rapidly display resistance to lincomycin when exposed to both erythromycin and lincomycin.<sup>1,2</sup> U.S. prescribing information for lincomycin and clindamycin similarly describe in vitro antagonism between these agents and erythromycin.<sup>3,4,5</sup> Due to the possible clinical significance of such antagonism, prescribing information for lincomycin and clindamycin products, including topical clindamycin products, recommends avoiding use with erythromycin.<sup>3,4,5</sup><br><br>The specific mechanism of antagonism between these agents is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Griffith LJ, Ostrander WE, Mullins CG, Beswick DE. Drug antagonism between lincomycin and erythromycin. <i>Science</i>. 1965;147(3659):746-747. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14242023\">[PubMed 14242023]</a></p>\n<p>2. Annear DI. Interaction between erythromycin and lincomycin in <i>Streptococcus pyogenes</i>. <i>J Med Microbiol</i>. 1978;11(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=351184\">[PubMed 351184]</a></p>\n<p>3. <i>Cleocin Phosphate</i> (clindamycin phosphate) [prescribing information]. New York, NY: Pfizer Inc; April 2008.</p>\n<p>4. <i>Lincocin</i> (lincomycin) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company; June 2007.</p>\n<p>5. <i>Acanya</i> (clindamycin and benzoyl peroxide) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8309":"<p><b>Title</b> Clindamycin (Topical) / Erythromycin (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Erythromycin (Topical) may diminish the therapeutic effect of Clindamycin (Topical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of topical erythromycin and topical clindamycin at the same application site.</p> \n<p><b>Discussion</b> In vitro studies have demonstrated antagonism between erythromycin and lincomycin whereby strains of <i>Staphylococcus</i> spp. And <i>Streptococcus pyogenes</i> that are resistant to erythromycin rapidly display resistance to lincomycin when exposed to both erythromycin and lincomycin.<sup>1,2</sup> U.S. prescribing information for lincomycin and clindamycin similarly describe in vitro antagonism between these agents and erythromycin.<sup>3,4,5</sup> Due to the possible clinical significance of such antagonism, prescribing information for lincomycin and clindamycin products, including topical clindamycin products, recommends avoiding use with erythromycin.<sup>3,4,5</sup> Labeling for at least one topical clindamycin product states that its use even with topical erythromycin should be avoided, presumably based on the theoretical potential for antagonism between the agents when applied to the same site.<sup>5</sup><br><br>The specific mechanism of antagonism between these agents is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Griffith LJ, Ostrander WE, Mullins CG, Beswick DE. Drug antagonism between lincomycin and erythromycin. <i>Science</i>. 1965;147(3659):746-747. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14242023\">[PubMed 14242023]</a></p>\n<p>2. Annear DI. Interaction between erythromycin and lincomycin in <i>Streptococcus pyogenes</i>. <i>J Med Microbiol</i>. 1978;11(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=351184\">[PubMed 351184]</a></p>\n<p>3. <i>Cleocin Phosphate</i> (clindamycin phosphate) [prescribing information]. New York, NY: Pfizer Inc; April 2008.</p>\n<p>4. <i>Lincocin</i> (lincomycin) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company; June 2007.</p>\n<p>5. <i>Acanya</i> (clindamycin and benzoyl peroxide) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8310":"<p><b>Title</b> Neuromuscular-Blocking Agents / Clindamycin (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clindamycin (Topical) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for prolonged/enhanced neuromuscular blockade in patients using neuromuscular-blocking agents in combination with topical clindamycin.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for topical clindamycin products warns that their use in combination with neuromuscular-blocking agents may result in enhanced neuromuscular blockade.<sup>1,2</sup> While specific data describing these effects with topical clindamycin have not been published, several case reports describe increased duration and/or intensity of pharmacologic effects of neuromuscular blocking agents with concomitant administration of systemic lincosamide antibiotics.<sup>3,4,5,6,7</sup><br><br>An interaction between these agents could occur based on the independent neuromuscular blocking activities of the individual agents. Clindamycin may exhibit neuromuscular blocking activity independent of coadministration of other neuromuscular blocking agents.<sup>1,2,8</sup> However, systemic clindamycin exposure following topical application is very low relative to that following administration of systemic products, suggesting a substantially reduced risk with topical products.<sup>1,2,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cleocin T</i> (clindamycin) [prescribing information]. New York, NY: Pfizer Inc; April 2014.</p>\n<p>2. <i>Acanya</i> (clindamycin and benzoyl peroxide) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2014.</p>\n<p>3. Sloan PA, Rasul M. Prolongation of rapacuronium neuromuscular blockade by clindamycin and magnesium. <i>Anesth Analg</i>. 2002;94(1):123-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11772813\">[PubMed 11772813]</a></p>\n<p>4. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced neuromuscular blockade by clindamycin. <i>Anesthesiology</i>. 1974;41(4):407-408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4415332\">[PubMed 4415332]</a></p>\n<p>5. Booij LH, Miller RD, Crul JF. Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium neuromuscular blockade in man. <i>Anesth Analg</i>. 1978;57(3):316-321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=566050\">[PubMed 566050]</a></p>\n<p>6. Avery D, Finn R. Succinylcholine-prolonged apnea associated with clindamycin and abnormal liver function tests. <i>Dis Nerv Syst</i>. 1977;38(6):473-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=862507\">[PubMed 862507]</a></p>\n<p>7. Jedeikin R, Dolgunski E, Kaplan R, Hoffman S. Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. <i>Anaesthesia</i>. 1987;42(8):858-860. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2889390\">[PubMed 2889390]</a></p>\n<p>8. al Ahdal O, Bevan DR. Clindamycin-induced neuromuscular blockade. <i>Can J Anaesth</i>. 1995;42(7):614-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7553999\">[PubMed 7553999]</a></p>\n<p>9. <i>Cleocin Phosphate</i> (clindamycin phosphate) [prescribing information]. New York, NY: Pfizer Inc; April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8311":"<p><b>Title</b> Voriconazole / Efavirenz</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: An Australian efavirenz product (Stocrin brand) specifically contraindicates this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Efavirenz. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of standard voriconazole doses with efavirenz doses of 400 mg/day or higher is contraindicated. If these drugs are to be coadministered, the voriconazole oral maintenance dose should be increased to 400 mg every 12 hours, and the efavirenz dose should be reduced to 300 mg/day. Because of this, certain fixed-dose combinations containing efavirenz cannot be used with voriconazole. The Atripla combination product (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) specifically contraindicates use with voriconazole. Similarly, an Australian efavirenz product also contraindicates this combination. Monitor patient clinical response to the combination closely.</p> \n<p><b>Discussion</b> The voriconazole AUC and maximum serum concentration (Cmax) were an average of 77% to 80% lower and 61% to 66% lower, respectively, when voriconazole (200 mg twice daily) was given with efavirenz 400 mg/day in studies of healthy volunteers.<sup>1,2</sup> These results support the conclusions of a case report that described a breakthrough Candida infection in a patient who was stable on efavirenz and then was started on voriconazole.<sup>3</sup> A subsequent increase of the patient's voriconazole dose resulted in clinical improvement.<br><br>An increase in the voriconazole dose to 400 mg twice daily given with a reduced dose of efavirenz (to 300 mg/day) appears to largely minimize the impact of this interaction. The average voriconazole AUC was decreased by 7% and the average Cmax was 23% higher (compared to concentrations obtained at a dose of 400 mg twice daily for 1 day, then 200 mg twice daily for 2 days) when voriconazole 400 mg twice daily was given together with efavirenz 300 mg/day in a study of 16 healthy volunteers.<sup>4</sup>. The average voriconazole AUC and Cmax were 55% and 38% lower, respectively, with a lesser voriconazole dose increase to 300 mg twice daily.<sup>4</sup><br><br>The mechanism for this apparent interaction is uncertain but likely related to efavirenz-mediated induction of voriconazole metabolism by CYP2C9, CYP2C19, and/or CYP2B6.<sup>1,2,4,5</sup><br><br>Additionally, the average efavirenz AUC was 43% to 44% higher with concurrent voriconazole (200 mg twice daily) in studies of healthy volunteers.<sup>1,2</sup> A reduced efavirenz dose (300 mg/day) given with an increased voriconazole dose of 400 mg twice daily was associated with an average 17% increase in efavirenz AUC (as compared to efavirenz 600 mg/day without voriconazole).<sup>4</sup> This aspect of the interaction is likely the result of voriconazole-mediated inhibition of efavirenz metabolism by CYP3A.<sup>2</sup><br><br>An Australian efavirenz product specifically contraindicates this combination.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. <i>J Clin Pharmacol</i>. 2008;48(1):73-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18025525\">[PubMed 18025525]</a></p>\n<p>2. Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc, February 2014.</p>\n<p>3. Gerzenshtein L, Patel SM, Scarsi KK, Postelnick MJ, Flaherty JP. Breakthrough Candida infections in patients receiving voriconazole. <i>Ann Pharmacother</i>. 2005;39(7-8):1342-1345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15914520\">[PubMed 15914520]</a></p>\n<p>4. Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2008;65(4):523-530. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18294336\">[PubMed 18294336]</a></p>\n<p>5. Xu C, Ogburn ET, Guo Y, Desta Z. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. <i>Drug Metab Dispos</i>, 2012;40(4):717-725. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22232427\">[PubMed 22232427]</a></p>\n<p>6. Stocrin (efavirenz) [product information]. Macquarie Park, New South Wales, Australia: Merck Sharp &amp; Dohme (Australia) PTY Limited; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8312":"<p><b>Title</b> Everolimus / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Everolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use of voriconazole with everolimus is not recommended. If this combination must be used, close monitoring of everolimus concentrations is critical, and substantial (eg, at least 75%) dose reductions will likely be necessary. Monitor closely for everolimus adverse effects and toxicity.</p> \n<p><b>Discussion</b> The labeling for both voriconazole and everolimus warn that use of the combination is not recommended since it is predicted that the combination would result in increased everolimus concentrations.<sup>1,2</sup> Concomitant voriconazole treatment with everolimus in lung transplant patients resulted in a significant 8.7-fold increase in the everolimus concentration/dose ratio, necessitating an 87% reduction in everolimus dose.<sup>3</sup> The addition of voriconazole to everolimus resulted in an approximate 5-fold increase in everolimus trough concentration and led to worsening pneumonitis in renal transplant patient.<sup>4</sup> In another renal transplant patient, there was a 7.5-fold increase in everolimus trough concentrations with concomitant use of voriconazole.<sup>5</sup> Another case describes a patient treated with everolimus who developed nephrotic syndrome within two months of voriconazole initiation.<sup>6</sup> The patient's condition improved 10 days after discontinuation of both drugs, and voriconazole was later restarted without problem. Increased everolimus concentrations and effects were implicated as the cause of the patient's nephrotic syndrome.<br><br>The likely mechanism for this interaction is voriconazole inhibition of the CYP3A4-mediated metabolism of everolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zortress (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2010.</p>\n<p>2. Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; February 2014.</p>\n<p>3. Outeda Macias M, Salvador Garrido P, Elberdin Pazos L, Martin Herranz MI. Management of everolimus and voriconazole interaction in lung transplant patients. <i>Ther Drug Monit</i>. 2016;38(3):305-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26926669\">[PubMed 26926669]</a></p>\n<p>4. Lecefel C, Eloy P, Chauvin B, et al. Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient. <i>J Clin Pharm Ther</i>. 2015;40(1):119-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25417855\">[PubMed 25417855]</a></p>\n<p>5. Billaud EM, Antoine C, Berge M, et al. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. <i>Clin Drug Investig</i>. 2009;29(7):481-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19499965\">[PubMed 19499965]</a></p>\n<p>6. Tran PN, Pinter-Brown LC. Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma. <i>J Clin Pharm Ther</i>. 2017; Jun 29 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28661568\">[PubMed 28661568]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8313":"<p><b>Title</b> MetFORMIN / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of MetFORMIN. Specifically, alcohol may potentiate the risk of lactic acidosis <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the intake of excessive amounts of alcohol (acute or chronic ingestion) while taking metformin.</p> \n<p><b>Discussion</b> Lactic acidosis is a rare, but serious adverse event reported with metformin therapy.<sup>1</sup> Acute alcohol ingestion alone has been reported to cause lactic acidosis.<sup>2,3</sup> Combining alcohol with metformin may potentiate the risk for the development of lactic acidosis. U.S. prescribing information contains a boxed warning about the risk of lactic acidosis with excessive alcohol intake.<sup>1</sup><br><br>In a study of 4 patients treated for a week with metformin or phenformin (another biguanide), lactate levels were measured before and 2 hours after administration of 30 g of oral ethanol. Lactate levels increased significantly after alcohol ingestion, though no patient developed lactic acidosis.<sup>4</sup> In another trial, 5 patients were given 34 g of oral ethanol, then treated for 2 weeks with phenformin, and then given 34 g of oral ethanol again. Lactate levels were measured after both alcohol ingestions. There was no change in lactate concentration after the ethanol ingestion alone, but blood lactate levels rose significantly when combined with phenformin. Lactic acidosis did not occur in any patient.<sup>5</sup> <br><br>Acute alcohol ingestion has been implicated as a possible contributing factor in reports of metformin and phenformin induced lactic acidosis.<sup>6,7,8</sup><br><br>The mechanism by which ethanol may potentiate the risk of metformin induced lactic acidosis is not completely understood, but may relate to increased lactate production accompanied by decreased lactate clearance.<sup>8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Glucophage</i> (metformin). [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; August 2008.</p>\n<p>2. Lien D, Mader TJ. Survival from profound alcohol-related lactic acidosis. <i>J Emerg Med</i>. 1999;17(5):841-846. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10499700\">[PubMed 10499700]</a></p>\n<p>3. Mussig K, Schleicher ED, Haring HU, Riessen R. Satisfactory outcome after severe ethanol-induced lactic acidosis and hypoglycemia. <i>J Emerg Med</i>. 2008;34(3):337-338. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18155381\">[PubMed 18155381]</a></p>\n<p>4. Schaffalitzky de Muckadell OB, Mortensen H, Lyngsoe J. Metabolic effects of glucocorticoid and ethanol administration in phenformin- and metformin-treated obese diabetics. <i>Acta Med Scand</i>. 1979;206(4):269-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=506799\">[PubMed 506799]</a></p>\n<p>5. Johnson HK, Waterhouse C. Relationship of alcohol and hyperlactatemia in diabetic subjects treated with phenoformin. <i>Am J Med</i>. 1968;45(1):98-104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5658874\">[PubMed 5658874]</a></p>\n<p>6. Issacs P. Alcohol and phenformin in diabetes. <i>Br Med J</i>. 1970;3(5725):773-774. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5472774\">[PubMed 5472774]</a></p>\n<p>7. Shirriffs GG, Bewsher PD. Hypothermia, abdominal pain, and lactic acidosis in phenformin-treated diabetic. <i>Br Med J</i>. 1970;3(5721):506. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4989326\">[PubMed 4989326]</a></p>\n<p>8. Krzymien J, Karnafel W. Lactic acidosis in patients with diabetes. <i>Pol Arch Med Wewn</i>. 2013;123(3):91-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23299861\">[PubMed 23299861]</a></p>\n<p>9. McGuire LC, Cruickshank AM, Munro PT. Alcoholic ketoacidosis. <i>Emerg Med J</i>. 2006;23(6):417-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16714496\">[PubMed 16714496]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8314":"<p><b>Title</b> Vitamin K Antagonists / Econazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Econazole may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased warfarin response (increased INR, signs/symptoms of bleeding) if a patient on warfarin begins topical econazole. Particular caution is warranted for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A case report describes a 79 year old male on chronic warfarin therapy who experienced bruising, bleeding, and an INR of 12 after initiation of econazole cream applied to the scrotum and inner thighs.<sup>1</sup> A second case report describes an 84 year old female on chronic acenocoumarol therapy who developed a cervical hematoma, airway obstruction, and an INR exceeding the laboratory limits after beginning treatment with econazole lotion for extensive dermatitis covering 12% of her body surface area.<sup>2</sup> In vivo concentrations of econazole are usually negligible with topical application, with less than 1% of the applied dose recovered in the urine and feces.<sup>3</sup> However, when the product is applied to large areas of the body, in the genital region, or used under occlusion, increases in systemic absorption may occur.<sup>3,4</sup><br><br>The likely mechanism of this reported interaction is econazole-mediated inhibition of CYP450 isoenzymes involved in warfarin and acenocoumarol metabolism.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lang PG Jr., LeClercq AH. Increase in anticoagulant effect of warfarin in a patient using econazole cream. <i>J Am Acad Dermatol</i>. 2006;55(suppl 5):S117-S119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17052529\">[PubMed 17052529]</a></p>\n<p>2. Wey PF, Petitjeans F, Lions C, Ould-Ahmed M, Escarment J. Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. <i>Am J Geriatr Pharmacother</i>. 2008;6(3):173-177 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18775393\">[PubMed 18775393]</a></p>\n<p>3. <i>Spectazole</i> (econazole). [prescribing information]. Greensboro, NC: Merz Pharmaceuticals, LLC; February 2014.</p>\n<p>4. <i>Prevaryl</i> (econazole). [summary of product characteristics]. High Wycombe, Buckingshamshire, GB: Janssen-Cilag Ltd; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8316":"<p><b>Title</b> Vitamin K Antagonists / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may decrease the serum concentration of Vitamin K Antagonists. More specifically, this effect has been described in heavy drinking alcoholic patients (over 250 g alcohol daily for over 3 months). The role of alcohol itself is unclear. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor INR in patients who begin consistently drinking heavily, or who greatly reduce alcohol consumption following periods of consistent heavy drinking.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> In a clinical study, the plasma half-life of warfarin (40 mg single oral dose) was roughly 36% lower in 15 alcoholic patients (consuming greater than 250 g daily for over 3 months, with inadequate diet but no persistent abnormalities in liver function tests) compared to 11 healthy volunteers reporting little or no alcohol consumption (less than 40 g every 2 weeks).<sup>1</sup> In contrast, clinical study findings in non-alcoholic patients consistently suggest little or no interaction between warfarin and alcohol. In one study of 21 patients receiving warfarin for venous thromboembolism, consumption of 375 mL of wine (half a standard bottle, 41 g alcohol) was associated with no change in anticoagulant activity.<sup>2</sup> Additional studies of healthy volunteers found no impact of 21 days of concomitant use of up to 57 g of alcohol daily during mealtime, or up to 47 g of alcohol daily while fasting, on warfarin plasma concentrations and anticoagulant effects.<sup>3,4</sup> A single published case report does describe a substantial increase in INR (from just over 2 up to 8) after a 58 year old patient began drinking half a light beer daily.<sup>5</sup> One other case report describes a patient who experienced a drop in warfarin concentration and effects following discontinuation of moderate alcohol consumption (50 mL whiskey daily).<sup>6</sup> Rechallenge with alcohol and a second dechallenge both suggested that the changes in warfarin exposure and effects were related to alcohol rather than other factors.<br><br>Several database reviews and risk factor analyses have identified a possible association between alcohol consumption, or a recent increase in alcohol consumption, and bleeding in patients receiving warfarin or acenocoumarol.<sup>7,8,9,10</sup> Analyses have also found an association between reported alcohol abuse and both supratherapeutic INR and overall time outside the desired INR range in warfarin treated patients.<sup>11,12</sup> However, one analysis found no association between increased alcohol consumption and rates of supratherapeutic INR,<sup>13</sup> another suggested that habitual moderate alcohol intake may reduce the risk of INR elevations above 6,<sup>14</sup> and a third suggested a higher risk of INR elevations above 6 in patients who recently decreased alcohol intake.<sup>15</sup> Studies of the impact of alcohol consumption on the risk of serious bleeding independent of anticoagulant use have found variable effects (potentially causative, protective, or neutral).<sup>16,17,18,19,20</sup><br><br>The mechanism of the possible interaction between alcohol and vitamin K antagonists has not been fully explored. Ethanol can inhibit CYP2C9 mediated metabolism of S-warfarin (the more potent isomer) and displace warfarin from protein binding sites in vitro.<sup>21,22,23</sup> However, the lack of impact of ethanol consumption on warfarin concentrations and effects in multiple clinical studies casts doubt on the clinical significance of these observations for most patients.<sup>2,3,4</sup> Chronic heavy alcohol consumption may induce CYP2C9 and/or other enzymes mediating warfarin metabolism, but based on the poor reproducibility of the apparent CYP2C9 induction effect with ethanol rechallenge in one clinical study these changes may be a result of chronic changes in alcoholism (e.g., malnutrition) rather than of alcohol itself.<sup>24</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kater RM, Roggin G, Tobon F, Zieve P, Iber FL. Increased rate of clearance of drugs from the circulation of alcoholics. <i>Am J Med Sci</i>. 1969;258(1):35-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4894493\">[PubMed 4894493]</a></p>\n<p>2. Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. <i>Acta Med Scand</i>. 1986;220(4):347-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3541503\">[PubMed 3541503]</a></p>\n<p>3. O'Reilly RA. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. <i>Am J Med Sci</i>. 1979;277(2):189-194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=463946\">[PubMed 463946]</a></p>\n<p>4. O'Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. <i>Arch Intern Med</i>. 1981;141(4):458-459. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7212888\">[PubMed 7212888]</a></p>\n<p>5. Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. <i>Pharmacotherapy</i>. 2005;25(2):303-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767245\">[PubMed 15767245]</a></p>\n<p>6. Breckenridge A, Orme M. Clinical implications of enzyme induction. <i>Ann N Y Acad Sci</i>. 1971;179:421-431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5285387\">[PubMed 5285387]</a></p>\n<p>7. Pagano MB, Chandler WL. Bleeding risks and response to therapy in patients with INR higher than 9. <i>Am J Clin Pathol</i>. 2012;138(4):546-550. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23010709\">[PubMed 23010709]</a></p>\n<p>8. Gallego P, Roldan V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. <i>Circ Arrhythm Electrophysiol</i>. 2012;5(2):312-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22319005\">[PubMed 22319005]</a></p>\n<p>9. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. <i>Pharmacotherapy</i>. 2007;27(9):1237-1247. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17723077\">[PubMed 17723077]</a></p>\n<p>10. McGriff-Lee NJ, Csako G, Chen JT, et al; Anticoagulation Working Group. Search for predictors of nontherapeutic INR results with warfarin therapy. <i>Ann Pharmacother</i>. 2005;39(12):1996-2002. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16288081\">[PubMed 16288081]</a></p>\n<p>11. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). <i>J Thromb Haemost</i>. 2010;8(10):2182-2191. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653840\">[PubMed 20653840]</a></p>\n<p>12. Doecke CJ, Cosh DG, Gallus AS. Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response. <i>Aust N Z J Med</i>. 1991;21(3):319-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1953510\">[PubMed 1953510]</a></p>\n<p>13. Mukamal KJ, Smith CC, Karlamangla AS, Moore AA. Moderate alcohol consumption and safety of lovastatin and warfarin among men: the post-coronary artery bypass graft trial. <i>Am J Med</i>. 2006;119(5):434-440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16651056\">[PubMed 16651056]</a></p>\n<p>14. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. <i>JAMA</i>. 1998;279(9):657-662. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9496982\">[PubMed 9496982]</a></p>\n<p>15. Penning-van Beest FJ, Geleijnse JM, van Meegen E, Vermeer C, Rosendaal FR, Stricker BH. Lifestyle and diet as risk factors for overanticoagulation. <i>J Clin Epidemiol</i>. 2002;55(4):411-417. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11927211\">[PubMed 11927211]</a></p>\n<p>16. Martini SR, Flaherty ML, Brown WM, et al. Risk factors for intracerebral hemorrhage differ according to hemorrhage location. <i>Neurology</i>. 2012;79(23):2275-2282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23175721\">[PubMed 23175721]</a></p>\n<p>17. Garcia-Rodriguez LA, Gaist D, Morton J, Cookson C, Gonzalez-Perez A. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. <i>Neurology</i>. 2013;81(6):566-574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23843464\">[PubMed 23843464]</a></p>\n<p>18. Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. <i>Stroke</i>. 2007;38(10):2718-2725. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17761915\">[PubMed 17761915]</a></p>\n<p>19. O'Donnell MJ, Xavier D, Liu L, et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. <i>Lancet</i>. 2010;376(9735):112-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20561675\">[PubMed 20561675]</a></p>\n<p>20. McGrath ER, Kapral MK, Fang J, et al; Investigators of the Registry of the Canadian Stroke Network. Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation? <i>Stroke</i>. 2012;43(8):2048-2054. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22618379\">[PubMed 22618379]</a></p>\n<p>21. Tatsumi A, Ikegami Y, Morii R, Sugiyama M, Kadobayashi M, Iwakawa S. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1. <i>Biol Pharm Bull</i>. 2009;32(3):517-519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19252308\">[PubMed 19252308]</a></p>\n<p>22. Tatsumi A, Kadobayashi M, Iwakawa S. Effect of ethanol on the binding of warfarin enantiomers to human serum albumin. <i>Biol Pharm Bull</i>. 2007;30(4):826-829. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17409531\">[PubMed 17409531]</a></p>\n<p>23. Ha CE, Petersen CE, Park DS, Harohalli K, Bhagavan NV. Investigations of the effects of ethanol on warfarin binding to human serum albumin. <i>J Biomed Sci</i>. 2000;7(2):114-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10754385\">[PubMed 10754385]</a></p>\n<p>24. Iber FL. Drug metabolism in heavy consumers of ethyl alcohol. <i>Clin Pharmacol Ther</i>. 1977;22(5 pt 2):735-742. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=913032\">[PubMed 913032]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8317":"<p><b>Title</b> Progestins (Contraceptive) / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Women taking efavirenz should use an alternative or additional method of contraception due to the possibility for decreased contraceptive effectiveness. The efavirenz prescribing information specifically recommends use of a barrier contraceptive during concurrent use and for 12 weeks after discontinuation of efavirenz. This recommendation does include women who are using implanted etonorgestrel. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction and may be used without a need for additional contraception. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The average AUCs of the progestins levonogestrel, 17-deacetylnorgestimate (active metabolite of norgestimate), and etonorgestrel AUC were reduced by 56% to 86%, 64%, and 61%, respectively, with concurrent efavirenz or efavirenz-based antiretroviral therapy in several different studies.<sup>2,3,4</sup> Similarly, 25% (4/16) of HIV-positive women taking ethinyl estradiol/desogestrel and treated with an efavirenz-based regimen had an elevated concentration of endogenous progesterone, indicating possible lack of contraceptive effectiveness (including 3/16 whose progesterone concentrations were sufficiently elevated to indicate possible ovulation).<sup>5</sup> By comparison, none of 18 women treated with a nevirapine-based regimen had similarly elevated serum progesterone concentrations. These results all support reported cases of clinical contraceptive failure in women receiving efavirenz, including multiple women who were using implanted etonorgestrel.<sup>6,7</sup> In contrast to the above findings, several studies (n=15 to 17) of depot medroxyprogesterone acetate reported no significant difference in medroxyprogesterone concentrations with concurrent use of efavirenz-containing antiviral therapies.<sup>8,9,10</sup><br><br>Consistent with these findings, guidelines recommend that women taking efavirenz should use an alternative or additional method of contraception due to the possibility for decreased contraceptive effectiveness.<sup>11</sup> This recommendation extends also to implanted etonorgestrel, though contraceptive implants have demonstrated increased efficacy in preventing pregnancies when compared to oral contraceptives.<sup>12</sup> A clinical study of 24,450 HIV-positive women demonstrated that the incidence of pregnancy in women treated with efavirenz-based regimen was 3.3 per 100 person-years when using contraceptive implants versus 5.4 per 100 person-years when using depot medroxyprogesterone.<sup>12</sup> In contrast, the incidence of pregnancy in those treated with nevirapine-based regimen was 1.1 per 100 person-years when using contraceptive implants versus 4.5 per 100 person-years when using depot medroxyprogesterone. These results demonstrate both that efavirenz appears to significantly impair the effectiveness of implanted contraceptives, as compared to the impact of nevirapine, and that implanted contraceptives may be more effective than depot medroxyprogesterone, particularly among efavirenz-treated patients.<sup>12</sup> Additionally, mean levonorgestrel concentrations were 47% and 57% lower in efavirenz-treated women than in ART-naive women at weeks 24 and 48, respectively, according to a clinical study of a levonorgestrel contraceptive implant used in ART-naive women (n=17), women receiving efavirenz-based therapy (n=20), and women receiving nevirapine-based therapy (n=20).<sup>13</sup> Three pregnancies occurred in the efavirenz group between 36-48 weeks of contraceptive implant use, while none occurred in the ART-naive and nevirapine groups.<sup>13</sup><br><br>The mechanism for this observed interaction is likely efavirenz induction of the hepatic metabolism of contraceptive progestins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Landolt NK, Phanuphak N, Ubolyam S, et al. Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. <i>J Acquir Immune Defic Syndr</i>. 2014;66(2):e50-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24608892\">[PubMed 24608892]</a></p>\n<p>3. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. <i>Infect Dis Obstet Gynecol</i>. 2012;2012:137192. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22536010\">[PubMed 22536010]</a></p>\n<p>4. Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. <i>Antivir Ther</i>. 2011;16(2):149-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21447863\">[PubMed 21447863]</a></p>\n<p>5. Landolt NK, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. <i>J Acquir Immune Defic Syndr</i>. 2013;62(5):534-539. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23187949\">[PubMed 23187949]</a></p>\n<p>6. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. <i>Contraception</i>. 2012;85(4):425-427. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22036046\">[PubMed 22036046]</a></p>\n<p>7. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. <i>J Fam Plann Reprod Health Care</i>. 2007;33(4):277-278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17925115\">[PubMed 17925115]</a></p>\n<p>8. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. <i>Contraception</i>. 2008;77(2):84-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18226670\">[PubMed 18226670]</a></p>\n<p>9. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. <i>Fertil Steril</i>. 2008;90(4):965-971. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17880953\">[PubMed 17880953]</a></p>\n<p>10. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. <i>Clin Pharmacol Ther</i>. 2007;81(2):222-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17192768\">[PubMed 17192768]</a></p>\n<p>11. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Updated March 28, 2014. Accessed April 16, 2014.</p>\n<p>12. Patel RC, Onono M, Gandhi M, et al. Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. <i>Lancet HIV</i>. 2015;2(11):e474-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26520927\">[PubMed 26520927]</a></p>\n<p>13. Scarsi KK, Darin KM, Nakalema S, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 Weeks. <i>Clin Infect Dis</i>. 2016;62(6):675-682. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26646680\">[PubMed 26646680]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8318":"<p><b>Title</b> Phendimetrazine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Phendimetrazine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that concurrent use of phendimetrazine with alcohol may result in adverse effects.</p> \n<p><b>Discussion</b> Phendimetrazine prescribing information warns that concurrent use of alcohol with phendimetrazine may be associated with adverse reactions.<sup>1</sup> No further information about the specific nature of the adverse reaction and/or the mechanism of any interaction is available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phendimetrazine [prescribing information]. Princeton, NJ: Sandoz Inc; October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8319":"<p><b>Title</b> Progestins (Contraceptive) / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Darunavir may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients who are taking darunavir/ritonavir should consider using an alternative or additional means of contraception. Injected depot medroxyprogesterone acetate is unlikely to participate in this interaction and may be used without a need for additional contraception. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Coadministration of darunavir/ritonavir (600 mg/100 mg twice daily) with ethinyl estradiol/norethindrone (35 mcg/1 mg) was associated with reductions in norethindrone AUC, maximum concentration, and minimum concentration (by 14%, 10%, and 30%, respectively).<sup>2</sup> The reduction in ethinyl estradiol exposure was even more substantial.<br><br>It is recommended that patients who are taking darunavir/ritonavir use an alternative or additional means of contraception.<sup>2,3,4</sup> Though darunavir/ritonavir had a more substantial impact on ethinyl estradiol concentrations than on the progestin (norethindone) concentration, guidelines include progestin-only and implanted etonogestrel in their recommendation to use alternative or additional contraception.<sup>4</sup> However, depot medroxyprogesterone is not included in this recommendation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Sekar VJ, Lefebvre E, Guzman SS, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. <i>Antivir Ther</i>. 2008;13(4):563-569. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18672535\">[PubMed 18672535]</a></p>\n<p>3. <i>Prezista</i> (darunavir) [Prescribing information]. Raritan, NJ: Tibotec Therapeutics, October 2008.</p>\n<p>4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Updated March 28, 2014. Accessed April 16, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8320":"<p><b>Title</b> Fosamprenavir / Progestins (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Progestins (Contraceptive) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients who are taking fosamprenavir (whether ritonavir-boosted or unboosted) should consider using an alternative or additional means of contraception. Injected depot medroxyprogesterone acetate is unlikely to participate in this interaction and may be used without a need for additional contraception. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Coadministration of fosamprenavir/ritonavir (700 mg/100 mg twice daily) with ethinyl estradiol/norethindrone (0.035 mg/0.5 mg) was associated with average 37% and 35% reductions in ethinyl estradiol AUC and norethindrone AUC, respectively (n=25).<sup>2</sup> Concentrations of amprenavir (the active metabolite of fosamprenavir) were not significantly altered.<br><br>Conversely, the average AUC of norethindrone was 18% higher and the average AUC of ethinyl estradiol was not significantly different when ethinyl estradiol/norethindrone (0.035 mg/1 mg) was coadministered with unboosted amprenavir 1200 mg twice daily (n=10).<sup>2</sup> Also, amprenavir AUC and minimum serum concentration (Cmin) were an average of 22% and 20% lower, respectively.<br><br>It is recommended that patients who are taking fosamprenavir (whether ritonavir-boosted or unboosted) should use an alternative or additional means of contraception.<sup>2,3</sup> These recommendations include progestin-only and implanted etonogestrel, but depot medroxyprogesterone is not included and may be used without a need for additional contraception.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. <i>Lexiva</i> (fosamprenavir) [Prescribing information]. Research Triangle Park, NC: ViiV Healthcare, February 2013.</p>\n<p>3. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Updated March 28, 2014. Accessed April 16, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8321":"<p><b>Title</b> Progestins (Contraceptive) / Lopinavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Non-oral progestin only contraceptives (injected depot medroxyprogesterone acetate, etonogestrel implants) appear less likely to be affected by coadministration with lopinavir/ritonavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lopinavir may decrease the serum concentration of Progestins (Contraceptive). Lopinavir may increase the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients taking lopinavir/ritonavir should consider an alternative or additional means of contraception. Injected depot medroxyprogesterone acetate and etonogestrel implants can likely be used without additional contraception. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The norethindrone AUC was an average of 17% lower when ethinyl estradiol/norethindrone (0.035 mg/1 mg daily) was given with lopinavir/ritonavir (400 mg/100 mg twice daily) in a study of 12 subjects summarized in the lopinavir/ritonavir prescribing information.<sup>2</sup> <br><br>Conversely, the median norelgestromin AUC was 83% higher (ethinyl estradiol AUC was 45% lower) when transdermal ethinyl estradiol/norelgestromin was administered in patients stable on lopinavir/ritonavir (n=8) as compared with patients not receiving highly active antiretroviral therapy (n=24).<sup>3</sup> In a study evaluating the effect of lopinavir/ritonavir on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA), the DMPA AUC increased 70% in 24 patients taking lopinavir/ritonavir compared with 14 historical controls receiving either no antiretroviral therapy or non-protease inhibitor regimens.<sup>4</sup> In another study, the etonogestrel AUC was 52% higher when an etonogestrel implant was used in 14 HIV-infected women taking lopinavir/ritonavir compared with 14 patients receiving no antiretroviral therapy.<sup>5</sup><br><br>The lopinavir/ritonavir prescribing information and clinical guidelines recommend that women taking lopinavir/ritonavir should use an alternative or additional method of contraception with oral hormonal contraceptives.<sup>2,6,7</sup> Guidelines specifically state that DMPA and etonogestrel implants do not appear to participate in this interaction and they may be used without need for additional contraception.<sup>6,7</sup> Recommendations for use of the transdermal patch (ethinyl estradiol/norelgestromin) are conflicting, as product labeling and the guidelines for use of antiretroviral drugs in women suggest using an alternative or an additional method of contraception,<sup>2,6</sup> while the guidelines for the use of antiretroviral agents in adults and adolescents state that no additional contraceptive method is necessary.<sup>7</sup> <br><br>The mechanism of this interaction is uncertain, but lopinavir- and/or ritonavir-mediated inhibition and/or induction of progestin metabolism is likely at least partially responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2015.</p>\n<p>3. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. <i>J Acquir Immune Defic Syndr</i>. 2010;55(4):473-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20842042\">[PubMed 20842042]</a></p>\n<p>4. Luque AE, Cohn SE, Park JG, et al. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. <i>Antimicrob Agents Chemother</i>. 2015;59(4):2094-2101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25624326\">[PubMed 25624326]</a></p>\n<p>5. Vieira CS, Bahamondes MV, de Souza RM, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. <i>J Acquir Immune Defic Syndr</i>. 2014;66(4):378-385. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24798768\">[PubMed 24798768]</a></p>\n<p>6. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Updated March 28, 2014. Accessed April 16, 2014.</p>\n<p>7. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Published April 2015. Accessed April 24, 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8322":"<p><b>Title</b> OXcarbazepine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of OXcarbazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients about the potential for greater CNS depressant effects with concurrent use of alcohol in patients being treated with oxcarbazepine. Patients should avoid this combination until they have discussed using these agents together with the healthcare provider who is monitoring their oxcarbazepine therapy and until they know how the oxcarbazepine affects them.</p> \n<p><b>Discussion</b> The oxcarbazepine prescribing information cautions that concurrent use with alcohol may result in greater sedation.<sup>1</sup> Fatigue, somnolence, and dizziness are all reported to occur more often with oxcarbazepine than with placebo in clinical trials (rates of 12% to 49% vs. 7% to 13%) summarized in the prescribing information.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Trileptal</i> (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8323":"<p><b>Title</b> Brentuximab Vedotin / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring for evidence of brentuximab vedotin toxicity (e.g., neuropathy, neutropenia, etc.) in patients receiving a strong P-glycoprotein inhibitor.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, co-administration of ketoconazole (a P-glycoprotein (P-gp) and CYP3A4 inhibitor) and brentuximab vedotin increased exposure to the active monomethyl auristatin E (MMAE) component of the antibody drug conjugate by 34%.<sup>1</sup> In vitro data show that MMAE is a substrate of both P-gp and CYP3A.<sup>2</sup> As MMAE is both metabolized and excreted as unchanged drug, the contribution of P-gp modulation on the disposition of MMAE relative to that of CYP3A modulation is unknown.<sup>1</sup> Accordingly, caution and increased monitoring for adverse effects are recommended when using brentuximab vedotin together with any strong P-gp inhibitor.<sup>2</sup><br><br>The mechanism of this possible interaction is likely decreased excretion of MMAE, leading to higher concentrations/exposure of this active microtubule disrupting compound, via P-gp inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. <i>J Clin Pharmacol</i>. 2013;53(8):866-877. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23754575\">[PubMed 23754575]</a></p>\n<p>2. <i>Adcetris</i> (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics Inc; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8324":"<p><b>Title</b> Brentuximab Vedotin / P-glycoprotein/ABCB1 Inducers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving this combination may experience reduced exposure to the active microtubule disrupting component of this antibody drug conjugate. Patients receiving brentuximab vedotin together with a strong P-glycoprotein inducer should be monitored closely for clinical response to treatment.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, co-administration of rifampin (a P-glycoprotein (P-gp) and CYP 3A4 inducer) and brentuximab vedotin reduced exposure to the active monomethyl auristatin E (MMAE) component by 46%.<sup>1</sup> In vitro data show that MMAE is a substrate of both P-gp and CYP3A.<sup>2</sup> As MMAE is both metabolized and excreted as unchanged drug, the contribution of P-gp modulation on the disposition of MMAE relative to that of CYP3A modulation is unknown.<sup>1</sup> Accordingly, caution is advised when using brentuximab vedotin together with any strong P-gp inducer.<sup>2</sup><br><br>The mechanism of this possible interaction is likely increased excretion of MMAE, leading to lower concentrations/exposure of this active microtubule disrupting compound, via P-gp induction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. <i>J Clin Pharmacol</i>. 2013;53(8):866-877. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23754575\">[PubMed 23754575]</a></p>\n<p>2. <i>Adcetris</i> (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics Inc; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8325":"<p><b>Title</b> Acetaminophen / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: Published data suggest a potentially elevated risk of acetaminophen hepatotoxicity in some alcoholic patients. Data supporting an elevated risk in other populations are sparse.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the hepatotoxic effect of Acetaminophen. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Acetaminophen hepatotoxicity has been reported in numerous published case reports involving alcoholic patients receiving acetaminophen doses typical of clinical practice (3-4 g/day or less). While the role of alcohol in these reactions is unclear, and the subpopulations at greatest risk of these effects have not been characterized, acetaminophen should be used cautiously and with close monitoring for clinical or laboratory evidence of hepatotoxicity in alcoholic patients.</p> \n<p><b>Discussion</b> Acetaminophen US prescribing information warns that it should be used cautiously in alcoholic patients.<sup>1</sup><br><br>Numerous published case reports describe hepatotoxicity (with features including substantial transaminase concentration elevations, prolonged prothrombin time, and hepatic necrosis) in chronic alcoholic patients following acetaminophen use.<sup>2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21</sup> Several of these cases include patients who took acetaminophen within clinically recommended dose limits (3-4 g/day or less). However, despite the large number of published case reports, acetaminophen use in recently-abstinent alcoholic patients, or in patients who consume 1-3 drinks/day (including during acetaminophen coadministration), has not been associated with any consistent alterations in liver function tests (e.g., transaminase concentrations, prothrombin time) in several placebo-controlled randomized trials.<sup>22,23,24,25,26,27</sup><br><br>The exact mechanism of any interaction between acetaminophen and alcohol is not clear. Alcohol may theoretically act as both an inhibitor and an inducer (this latter effect expected only with longer-term use) of CYP2E1, an enzyme that can convert acetaminophen to the hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).<sup>1,28,29</sup> Glutathione depletion in alcoholism could also theoretically decrease conjugation of NAPQI and further increase its hepatotoxic risk. Both acetaminophen and alcohol can also exert hepatotoxic effects independent of other agents. Human data supporting the proposed mechanisms of interaction between these agents are sparse, however, and the available clinical data suggest at best a very poorly generalizable mechanism of interaction between these agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ofirmev</i> (acetaminophen) [prescribing information]. San Diego, CA: Cadence Pharmaceuticals, Inc; October 2013.</p>\n<p>2. Licht H, Seeff LB, Zimmerman HJ. Apparent potentiation of acetaminophen hepatotoxicity by alcohol. <i>Ann Intern Med</i>. 1980;92(4):511. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7362155\">[PubMed 7362155]</a></p>\n<p>3. Barker JD Jr, de Carle DJ, Anuras S. Chronic excessive acetaminophen use and liver damage. <i>Ann Intern Med</i>. 1977;87(3):299-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=900673\">[PubMed 900673]</a></p>\n<p>4. McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL. Potentiation of acetaminophen hepatotoxicity by alcohol. <i>JAMA</i>. 1980;244(3):251-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7382090\">[PubMed 7382090]</a></p>\n<p>5. Leist MH, Gluskin LE, Payne JA. Enhanced toxicity of acetaminophen in alcoholics: report of three cases. <i>J Clin Gastroenterol</i>. 1985;7(1):55-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3980965\">[PubMed 3980965]</a></p>\n<p>6. Goldfinger R, Ahmed KS, Pitchumoni CS, Weseley SA. Concomitant alcohol and drug abuse enhancing acetaminophen toxicity. Report of a case. <i>Am J Gastroenterol</i>. 1978;70(4):385-388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=727190\">[PubMed 727190]</a></p>\n<p>7. Kaysen GA, Pond SM, Roper MH, Menke DJ, Marrama MA. Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen. <i>Arch Intern Med</i>. 1985;145(11):2019-2023. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4062453\">[PubMed 4062453]</a></p>\n<p>8. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. <i>Ann Intern Med</i>. 1986;104(3):399-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3511825\">[PubMed 3511825]</a></p>\n<p>9. O'Dell JR, Zetterman RK, Burnett DA. Centrilobular hepatic fibrosis following acetaminophen-induced hepatic necrosis in an alcoholic. <i>JAMA</i>. 1986;255(19):2636-2637. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3701979\">[PubMed 3701979]</a></p>\n<p>10. Lesser PB, Vietti MM, Clark WD. Lethal enhancement of therapeutic doses of acetaminophen by alcohol. <i>Dig Dis Sci</i>. 1986;31(1):103-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3940815\">[PubMed 3940815]</a></p>\n<p>11. Kartsonis A, Reddy KR, Schiff ER. Alcohol, acetaminophen, and hepatic necrosis. <i>Ann Intern Med</i>. 1986;105(1):138-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3717790\">[PubMed 3717790]</a></p>\n<p>12. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. <i>Hepatology</i>. 1995;22(3):767-773. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7657281\">[PubMed 7657281]</a></p>\n<p>13. Gerber MA, Kaufmann H, Klion F, Alpert LI. Acetaminophen associated hepatic injury. Report of two cases showing unusual portal tract reactions. <i>Hum Pathol</i>. 1980;11(1):37-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7364436\">[PubMed 7364436]</a></p>\n<p>14. Johnson MW, Friedman PA, Mitch WE. Alcoholism, nonprescription drug and hepatotoxicity. The risk from unknown acetaminophen ingestion. <i>Am J Gastroenterol</i>. 1981;76(6):530-533. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7331985\">[PubMed 7331985]</a></p>\n<p>15. Black M, Cornell JF, Rabin L, Shachter N. Late presentation of acetaminophen hepatotoxicity. <i>Dig Dis Sci</i>. 1982;27(4):370-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7067588\">[PubMed 7067588]</a></p>\n<p>16. Erickson RA, Runyon BA. Acetaminophen hepatotoxicity associated with alcoholic pancreatitis. <i>Arch Intern Med</i>. 1984;144(7):1509, 1513. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6732414\">[PubMed 6732414]</a></p>\n<p>17. Himmelstein DU, Woolhandler SJ, Adler RD. Elevated SGOT/SGPT ratio in alcoholic patients with acetaminophen hepatotoxicity. <i>Am J Gastroenterol</i>. 1984;79(9):718-720. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6475903\">[PubMed 6475903]</a></p>\n<p>18. Fleckenstein JL. Nyquil and acute hepatic necrosis. <i>N Engl J Med</i>. 1985;313(1):48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4000227\">[PubMed 4000227]</a></p>\n<p>19. Denison H, Kaczynski J, Wallerstedt S. Paracetamol medication and alcohol abuse: a dangerous combination for the liver and the kidney. <i>Scand J Gastroenterol</i>. 1987;22(6):701-704. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3659833\">[PubMed 3659833]</a></p>\n<p>20. Floren CH, Thesleff P, Nilsson A. Severe liver damage caused by therapeutic doses of acetaminophen. <i>Acta Med Scand</i>. 1987;222(3):285-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3425381\">[PubMed 3425381]</a></p>\n<p>21. Davis AM, Helms CM, Mitros FA, Wong YW, LaBrecque DR. Severe hepatic damage after acetaminophen use in psittacosis. <i>Am J Med</i>. 1983;74(2):349-352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6824012\">[PubMed 6824012]</a></p>\n<p>22. Heard K, Green JL, Bailey JE, Bogdan GM, Dart RC. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. <i>Aliment Pharmacol Ther</i>. 2007;26(2):283-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17593074\">[PubMed 17593074]</a></p>\n<p>23. Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. <i>Arch Intern Med</i>. 2001;161(18):2247-2252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11575982\">[PubMed 11575982]</a></p>\n<p>24. Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, Brands B. The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study. <i>Aliment Pharmacol Ther</i>. 2010;32(3):478-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20491750\">[PubMed 20491750]</a></p>\n<p>25. Kuffner EK, Green JL, Bogdan GM, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study. <i>BMC Med</i>. 2007;5:13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17537264\">[PubMed 17537264]</a></p>\n<p>26. Bartels S, Sivilotti M, Crosby D, Richard J. Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial. <i>Clin Toxicol (Phila)</i>. 2008;46(3):243-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18344107\">[PubMed 18344107]</a></p>\n<p>27. Rumack B, Heard K, Green J, et al. Effect of therapeutic doses of acetaminophen (up to 4 g/day) on serum alanine aminotransferase levels in subjects consuming ethanol: systematic review and meta-analysis of randomized controlled trials. <i>Pharmacotherapy</i>. 2012;32(9):784-791. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22851428\">[PubMed 22851428]</a></p>\n<p>28. Thummel KE, Slattery JT, Ro H, et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. <i>Clin Pharmacol Ther</i>. 2000;67(6):591-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10872641\">[PubMed 10872641]</a></p>\n<p>29. Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. <i>Alcohol Clin Exp Res</i>. 1996;20(1)(suppl):25A-28A. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8659683\">[PubMed 8659683]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8326":"<p><b>Title</b> Insulins / Glucagon-Like Peptide-1 Agonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Use of lixisenatide should be avoided in patients receiving both basal insulin and a sulfonylurea.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea.</p>\n<div>\n <p><b>Glucagon-Like Peptide-1 Agonists Interacting Members</b> Albiglutide, Dulaglutide, Exenatide, Lixisenatide, Semaglutide<br><b>Exception</b> Liraglutide</p>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> Manufacturers of all glucagon-like peptide-1 agonists warn that hypoglycemia has occurred when these agents were used in combination with insulin and that dose reductions of insulin should be considered in patients receiving both agents.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Byetta</i> (exenatide) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc; October 2009.</p>\n<p>2. <i>Victoza</i> (liraglutide) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; January 2010.</p>\n<p>3. <i>Tanzeum</i> (albiglutide) [prescribing information]. Wilmington, DE: GlaxoSmithKline LLC; April 2014.</p>\n<p>4. <i>Trulicity</i> (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; September 2014.</p>\n<p>5. <i>Lyxumia</i> (lixisenatide) [summary of product characteristics]. Singapore: Sanofi-Aventis Singapore; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8327":"<p><b>Title</b> Simvastatin / Albiglutide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Albiglutide may increase the serum concentration of Simvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Albiglutide prescribing information describes a pharmacokinetic study carried out to assess the effects of albiglutide on the single-dose oral pharmacokinetics of simvastatin (80 mg).<sup>1</sup> When albiglutide was co-administered with simvastatin, the maximum serum concentration (C<sub>max</sub>) of simvastatin and its active metabolite simvastatin acid was increased by approximately 18% and 98%, respectively. In the same trial, the AUC of simvastatin decreased by 40% and AUC of simvastatin acid increased by 36%.<sup>1</sup> The clinical relevance of these changes has not been established.<br><br>Albiglutide delays gastric emptying, which could explain a delay in achieving maximum concentration, but does not fully explain the increase in C<sub>max</sub> or the divergent changes in AUC of simvastatin and its active metabolite. The mechanism by which albiglutide may alter simvastatin concentrations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tanzeum</i> (albiglutide) [prescribing information]. Wilmington, DE: GlaxoSmithKline LLC; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8328":"<p><b>Title</b> Norethindrone / Albiglutide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Albiglutide may increase the serum concentration of Norethindrone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A pharmacokinetic study assessed the effects of albiglutide on the pharmacokinetics of the oral contraceptive ethinyl estradiol and norethindrone.<sup>1</sup> The maximum serum concentration (C<sub>max</sub>) and AUC of ethinyl estradiol were unchanged but the C<sub>max</sub> and AUC of norethindrone increased by 20% and 9% respectively. No clinically relevant pharmacodynamic effects on luteinizing hormone, follicle-stimulating hormone, or progesterone were observed. <sup>1,2</sup> <br><br>The mechanism by which albiglutide may increase norethindrone concentrations is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. <i>Postgrad Med</i>. 2012;124(6):55-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23322139\">[PubMed 23322139]</a></p>\n<p>2. <i>Tanzeum</i> (albiglutide) [prescribing information]. Wilmington, DE: GlaxoSmithKline LLC; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8329":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients treated with monoamine oxidase inhibitors (MAOIs) should avoid concomitant alcohol use.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for the MAOIs isocarboxazid, phenelzine, and tranylcypromine list alcohol use as a contraindication.<sup>1,2,3</sup> Although not listed as a contraindication, product labeling for both transdermal selegiline and moclobemide (available only in Canada) recommend avoidance of alcohol consumption.<sup>4,5</sup> Despite the absence of specific recommendations to avoid alcohol in the prescribing information of other medications known to inhibit monoamine oxidase,<sup>6,7,8,9</sup> similar risks likely apply.<br><br>While the reason for the listed contraindications are not explicitly stated, alcohol is a CNS depressant, so it may potentiate the CNS side effects of these MAOIs or may exacerbate the disease process in those patients using MAOIs for the treatment of depression. Furthermore, certain alcoholic beverages (beer, red wine, etc.) may provide additional sources of tyramine, thus increasing a patient’s risk for a hypertensive crisis.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Marplan</i> (isocarboxazid) [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; June 2007.</p>\n<p>2. <i>Nardil</i> (phenelzine) [prescribing information]. New York, NY: Pfizer; May 2007.</p>\n<p>3. <i>Parnate</i> (tranylcypromine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2008.</p>\n<p>4. <i>Apo-Moclobemide</i> (moclobemide) [product monograph]. Weston, Ontario, Canada: Apotex Inc; March 2009.</p>\n<p>5. <i>Emsam</i> (selegiline) [prescribing information]. Morgantown, WV: Somerset Pharmaceuticals Inc; January 2010.</p>\n<p>6. <i>Zyvox</i> (linezolid) [prescribing information]. New York, NY: Pfizer; September 2013.</p>\n<p>7. <i>Azilect</i> (rasagiline) [prescribing information]. Kansas City, MO: Teva Neuroscience Inc; December 2009.</p>\n<p>8. <i>Eldepryl</i> (selegiline) [prescribing information]. Tampa, FL: Somerset Pharmaceuticals Inc; January 2008.</p>\n<p>9. Methylene blue [prescribing information]. Shirley, NY: American Regent Inc; March 2011.</p>\n<p>10. Shulman KI, Tailor SA, Walker SE, Gardner DM. Tap (draft) beer and monoamine oxidase inhibitor dietary restrictions. <i>Can J Psychiatry</i>. 1997;42(3):310-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9114949\">[PubMed 9114949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8330":"<p><b>Title</b> Morphine (Liposomal) / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Morphine (Liposomal). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The effects of morphine may decrease if a rifamycin derivative is initiated/dose increased, or increase if a rifamycin derivative is discontinued/dose decreased. However, this interaction would theoretically not affect morphine that is absorbed and retained intrathecally.</p> \n<p><b>Discussion</b> The clearance of morphine (single 10 mg oral doses) was increased by approximately 50% in 10 normal subjects when administered following a 13-day course of rifampin (600 mg/day).<sup>1</sup> The analgesic effects of the morphine, as measured by a cold pressor test, were essentially abolished by rifampin pretreatment. The mechanism of this interaction is unknown. It may be related to the CYP isoenzyme-inducing effects of rifampin. Whether other rifamycin derivatives would affect morphine in a similar fashion is unknown.<br><br>Epidural administration of morphine sulfate liposomal results in part of the dose being absorbed intrathecally and part being absorbed systemically.<sup>2</sup> Based on the theoretical mechanism of the interaction, the fraction of the total morphine dose that is absorbed and retained intrathecally would not be affected by rifampin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fromm MF, Eckhardt K, Li S, et al, “Loss of Analgesic Effect of Morphine Due to Coadministration of Rifampin,” <i>Pain</i>, 1997, 72:261-7.</p>\n<p>2. Prescribing information. Depodur (morphine sulfate, lipid complex). Cedar Knolls, NJ: EKR Therapeutics, Inc, December 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8331":"<p><b>Title</b> Maraviroc / Efavirenz</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The management and significance of this drug interaction are different for patients also using a strong CYP 3A4 inhibitor compared to patients not taking a strong CYP 3A4 inhibitor.</p></li>\n <li><p><b>Renal Function</b>: The management of this drug interaction is different for patients with severe renal impairment (CrCl less than 30 mL/min) compared to patients without severe renal impairment.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Maraviroc. Of note, this effect only applies in the absence of a strong CYP3A4 inhibitor <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When used with efavirenz, the adult dose of maraviroc should be increased to 600 mg twice daily. However, this recommendation only applies in the absence of a concurrent strong CYP3A4 inhibitor, as data from such combinations suggest that the net effect remains CYP3A4 inhibition (and increased maraviroc concentrations). Maraviroc use is contraindicated in patients with severe renal impairment (CrCl less than 30 mL/min) receiving CYP3A4 inducers such as efavirenz.</p> \n<p><b>Discussion</b> Concurrent use of efavirenz (600 mg/day) with maraviroc (100 mg BID) for 14 days was associated with a mean 51% reduction in maraviroc AUC and a mean 56% reduction in maraviroc maximum serum concentration (C<sub>max</sub>) (n=12 subjects).<sup>1</sup> Similarly, two cohorts of a small study in HIV-positive subjects (n=8/cohort) report a mean 52%-53% decrease in maraviroc AUC and a mean 24%-33% decrease in maraviroc C<sub>max</sub> when a single dose of maraviroc (300 mg) was administered to subjects receiving regimens that contained the CYP3A4 inducer efavirenz (together with either lamivudine/zidovudine or didanosine and tenofovir).<sup>2</sup><br><br>As a part of one interaction study, a doubling of the maraviroc dose (from 100 mg BID to 200 mg BID) appeared to overcome the decreased drug concentrations associated with concurrent efavirenz use (mean 9% increase in AUC vs. lower dose maraviroc without efavirenz).<sup>1</sup> However, when maraviroc was administered with both a strong CYP 3A4 inhibitor (lopinavir/ritonavir or saquinavir/ritonavir) plus efavirenz, the net effect was an increase in maraviroc exposure, with a 253% (3.5-fold) and 500% (6-fold) increase in maraviroc AUC respectively.<sup>1</sup> <br><br>As a result of this interaction, maraviroc prescribing information recommends using an increased maraviroc dose (600 mg BID) when used with efavirenz.<sup>3</sup> However, if maraviroc is combined with efavirenz and a strong CYP 3A4 inhibitor the prescribing information recommends to decrease the maraviroc dose to 150 mg BID. Additionally, concomitant use of efavirenz and maraviroc is listed as a contraindication in patients with a CrCl less than 30 mL/min.<br><br>The mechanism of this interaction appears to be induction of CYP3A4-mediated maraviroc metabolism by efavirenz.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2008;65(suppl 1):38-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18333864\">[PubMed 18333864]</a></p>\n<p>2. Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. <i>Br J Clin Pharmacol</i>. 2008;65(suppl 1):54-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18333866\">[PubMed 18333866]</a></p>\n<p>3. <i>Selzentry</i> (maraviroc) [prescribing information]. Research Triangle Park, NC: Viiv Healthcare; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8332":"<p><b>Title</b> Maraviroc / Etravirine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The management and significance of this drug interaction are different for patients also using a strong CYP 3A4 inhibitor compared to patients not taking a strong CYP 3A4 inhibitor.</p></li>\n <li><p><b>Renal Function</b>: The management of this drug interaction is different for patients with severe renal impairment (CrCl less than 30 mL/min) compared to patients without severe renal impairment.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Etravirine may decrease the serum concentration of Maraviroc. Of note, this effect only applies in the absence of a strong CYP3A4 inhibitor <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When used with etravirine, the adult dose of maraviroc should be increased to 600 mg twice daily. However, this recommendation only applies in the absence of a concurrent strong CYP3A4 inhibitor, as data from such combinations suggest that the net effect remains CYP3A4 inhibition (and increased maraviroc concentrations). Maraviroc use is contraindicated in patients with severe renal impairment (CrCl less than 30 mL/min) receiving CYP3A4 inducers such as etravirine.</p> \n<p><b>Discussion</b> Concomitant use of etravirine (200 mg BID) with maraviroc (300 mg BID) for 10 days resulted in a 53% decrease in AUC, a 60% decrease in maximum serum concentration (C<sub>max</sub>), and a 40% decrease in trough concentrations (C<sub>min</sub>) of maraviroc.<sup>1</sup> Similar decreases in maraviroc AUC and C<sub>max</sub> were also seen when combined with efavirenz and rifampin, other CYP 3A4 inducers.<sup>2,3</sup><br><br>When maraviroc (150 mg BID) was administered with etravirine (200 mg BID) and a CYP 3A4 inhibitor (darunavir/ritonavir) for 10 days, maraviroc AUC increased by 210%, C<sub>max</sub> increased by 76%, and C<sub>min</sub> increased by 427%.<sup>1</sup><br><br>As a result of this interaction, maraviroc prescribing information recommends using an increased maraviroc dose (600 mg BID) when combined with etravirine.<sup>4</sup> However, if maraviroc is combined with etravirine and a strong CYP 3A4 inhibitor the prescribing information recommends to decrease the maraviroc dose to 150 mg BID. Additionally, concomitant use of etravirine and maraviroc is listed as a contraindication in patients with a CrCl less than 30 mL/min.<br><br>The mechanism of this interaction appears to be induction of CYP3A4-mediated maraviroc metabolism by etravirine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. <i>Antimicrob Agents Chemother</i>. 2011;55(5):2290-2296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383098\">[PubMed 21383098]</a></p>\n<p>2. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2008;65(suppl 1):38-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18333864\">[PubMed 18333864]</a></p>\n<p>3. Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. <i>Br J Clin Pharmacol</i>. 2008;65(suppl 1):54-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18333866\">[PubMed 18333866]</a></p>\n<p>4. <i>Selzentry</i> (maraviroc) [prescribing information]. Research Triangle Park, NC: Viiv Healthcare; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8333":"<p><b>Title</b> Digoxin / Polyethylene Glycol 4000</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral digoxin administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Polyethylene Glycol 4000 may decrease the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased digoxin concentrations during concomitant use of polyethylene glycol. Although no effective dose separation schedule has been established, administration of doses of polyethylene glycol and digoxin several hours apart could theoretically reduce the magnitude of interaction.</p> \n<p><b>Discussion</b> In a clinical study of 18 healthy volunteers, simultaneous coadministration of polyethylene glycol 4000 (20 g, on day 5 of an 8 day course receiving 20 g/day) decreased the maximum serum concentration and AUC of digoxin (0.5 mg single oral dose) by 40% and 30%, respectively.<sup>1</sup> No differences in digoxin heart rate lowering effects or AV conduction effects (the latter absent in both groups) were noted. <br><br>The mechanism of this interaction is not clear. Some in vitro data suggest that polyethylene glycol polymers may inhibit P-glycoprotein mediated digoxin efflux.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ragueneau I, Poirier JM, Radembino N, Sao AB, Funck-Brentano C, Jaillon P. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. <i>Br J Clin Pharmacol</i>. 1999;48(3):453-456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10510161\">[PubMed 10510161]</a></p>\n<p>2. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. <i>AAPS PharmSci</i>. 2002;4(4):E40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12646011\">[PubMed 12646011]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8334":"<p><b>Title</b> Digoxin / Polyethylene Glycol 3350</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral digoxin administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Polyethylene Glycol 3350 may decrease the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased digoxin concentrations during concomitant use of polyethylene glycol. Although no effective dose separation schedule has been established, administration of doses of polyethylene glycol and digoxin several hours apart could theoretically reduce the magnitude of interaction.</p> \n<p><b>Discussion</b> In a clinical study of 18 healthy volunteers, simultaneous coadministration of polyethylene glycol 4000 (20 g, on day 5 of an 8 day course receiving 20 g/day) decreased the maximum serum concentration and AUC of digoxin (0.5 mg single oral dose) by 40% and 30%, respectively.<sup>1</sup> No differences in digoxin heart rate lowering effects or AV conduction effects (the latter absent in both groups) were noted. <br><br>The mechanism of this interaction is not clear. Some in vitro data suggest that polyethylene glycol polymers may inhibit P-glycoprotein mediated digoxin efflux.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ragueneau I, Poirier JM, Radembino N, Sao AB, Funck-Brentano C, Jaillon P. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. <i>Br J Clin Pharmacol</i>. 1999;48(3):453-456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10510161\">[PubMed 10510161]</a></p>\n<p>2. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. <i>AAPS PharmSci</i>. 2002;4(4):E40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12646011\">[PubMed 12646011]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8335":"<p><b>Title</b> Fesoterodine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Fesoterodine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that consuming alcohol while taking fesoterodine may result in greater drowsiness and impairment of reaction time.</p> \n<p><b>Discussion</b> The fesoterodine prescribing information notes that somnolence has been associated with fesoterodine during post-marketing use, and the labeling cautions patients to avoid driving or operating heavy machinery until they are familiar with how fesoterodine affects them.<sup>1</sup> The prescribing information further warns that concurrent use of alcohol may enhance the drowsiness associated with fesoterodine use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Toviaz</i> (fesoterodine) [prescribing information]. New York, NY: Pfizer Inc, August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8336":"<p><b>Title</b> Oxybutynin / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Oxybutynin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that consuming alcohol while taking oxybutynin may result in greater drowsiness and impairment of reaction time.</p> \n<p><b>Discussion</b> The oxybutynin prescribing information notes that somnolence has been associated with oxybutynin use, and the labeling cautions patients to avoid driving or operating heavy machinery until they are familiar with how oxybutynin affects them.<sup>1</sup> The prescribing information further warns that concurrent use of alcohol may enhance the drowsiness associated with oxybutynin use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ditropan XL</i> (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc., July 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8337":"<p><b>Title</b> Trimethobenzamide / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Trimethobenzamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients that consuming alcohol while taking trimethobenzamide may result in greater drowsiness and impairment of reaction time.</p> \n<p><b>Discussion</b> The trimethobenzamide prescribing information cautions that trimethobenzamide may cause drowsiness and that patients should avoid driving or operating heavy machinery until they are familiar with how trimethobenzamide affects them.<sup>1</sup> The prescribing information further warns that concurrent use of alcohol may result in an adverse drug interaction with trimethobenzamide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tigan</i> (trimethobenzamide) [prescribing information]. Bristol, TN: King Pharmaceuticals, Inc., April, 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8338":"<p><b>Title</b> Amantadine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Amantadine. Alcohol may also cause dose-dumping for at least one extended-release amantadine product. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of alcohol with amantadine is not recommended. Caution patients that consuming alcohol while taking amantadine may result in a greater potential for adverse central nervous system side effects such as drowsiness, dizziness, or confusion. This may be a particular concern for the Gocovri brand product, where alcohol may increase the release of drug from the extended-release dosage form, possibly resulting in a substantial increase in amantadine concentrations and effects.</p> \n<p><b>Discussion</b> The prescribing information for amantadine products state that concurrent use of alcohol is not recommended,<sup>1,2</sup> or that patients should avoid excessive alcohol use.<sup>3</sup> Combined use may result in an increased risk for somnolence or other central nervous system (CNS) side effects. The prescribing information for the Gocovri brand product additionally states that concomitant use of alcohol may result in dose-dumping from the extended-release dosage form.<sup>1</sup> In vitro data show that 52% of the dose was released within 45 minutes and and up to 95% was released after 2 hours when in the presence of concentrations of 40% alcohol/0.1N HCl (time to maximum serum concentration is normally approximately 6 hours).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gocovri (amantadine) extended-release capsules [prescribing information]. Emeryville, CA: Adamas Pharma, LLC; August 2017.</p>\n<p>2. Osmolex ER (amantadine) extended-release tablets [prescribing information]. Bridgewater, NJ: Vertical Pharmaceuticals, LLC; February 2018.</p>\n<p>3. Amantadine [prescribing information]. Bridgewater, NJ: Alembic Pharmaceuticals Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8339":"<p><b>Title</b> Progestins (Contraceptive) / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Saquinavir may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients using ritonavir-boosted saquinavir should consider using an alternative or additional method of contraception. Injected depot medroxyprogesterone acetate is unlikely to participate in this interaction and may be used without need for additional contraception. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Though specific data concerning this combination are not available, professional guidelines caution that patients who are taking saquinavir/ritonavir should consider using an alternative or additional means of contraception, but that injected depot medroxyprogesterone acetate may be used without a need for additional contraception.<sup>2</sup><br><br><br>Ritonavir-boosted saquinavir is expected to decrease serum estrogen concentrations when used with estrogen-based contraceptive products,<sup>2,3,4</sup> and several other ritonavir-boosted protease inhibitors have been shown to decrease serum progestin concentrations when given with progestin-containing contraceptives.<sup>2</sup><br><br>The mechanism of this interaction is uncertain, but saquinavir- and/or ritonavir-mediated inhibition and/or induction of progestin metabolism is a possible mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Updated March 28, 2014. Accessed April 16, 2014.</p>\n<p>3. <i>Fortovase</i> (saquinavir) [prescribing information]. Nutley, NJ: Roche Laboratories Inc., September 2005.</p>\n<p>4. <i>Invirase</i> (saquinavir) [prescribing information]. South San Francisco, CA: Genentech USA, Inc., November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8340":"<p><b>Title</b> Terfenadine / Bicalutamide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bicalutamide may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of bicalutamide and terfenadine due to increased risk of QTc prolongation and torsades de pointes. The combination of bicalutamide and terfenadine is listed as a contraindication in the UK, Australian, and Singapore product labeling.</p> \n<p><b>Discussion</b> Given the ability of bicalutamide to inhibit CYP3A4, the enzyme primarily responsible for the metabolism of terfenadine, the resulting increased risk for QTc prolongation and torsades de pointes led several foreign bicalutamide manufacturers to state that use of bicalutamide and terfenadine is contraindicated.<sup>1,2,3</sup> US and Canadian labeling recommend caution when bicalutamide is combined with any CYP3A4 substrate but don’t mention terfenadine as a specific contraindication, likely due to its removal from US and Canadian markets.<sup>4,5</sup><br><br>The mechanism of this potential interaction is bicalutamide inhibition of CYP 3A4-mediated metabolism of terfenadine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Casodex</i> (bicalutamide) [summary of product characteristics]. Luton, Bedfordshire, England: AstraZeneca UK Limited; June 2012.</p>\n<p>2. <i>Cosudex</i> (bicalutamide) [summary of product characteristics]. North Ryde, New South Wales, Australia: AstraZeneca Pty Ltd; February 2010.</p>\n<p>3. <i>Casodex</i> (bicalutamide) [summary of product characteristics]. Plankstadt, Germany: Corden Pharma GmbH; June 2011.</p>\n<p>4. <i>Casodex</i> (bicalutamide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2010.</p>\n<p>5. <i>Casodex</i> (bicalutamide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8341":"<p><b>Title</b> Cisapride / Bicalutamide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bicalutamide may increase the serum concentration of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of bicalutamide and cisapride due to increased risk of QTc prolongation and torsades de pointes. The combination of bicalutamide and cisapride is listed as a contraindication in the UK, Australian, and Singapore product labeling.</p> \n<p><b>Discussion</b> Given the ability of bicalutamide to inhibit CYP3A4, the enzyme primarily responsible for the metabolism of cisapride, the resulting increased risk for QTc prolongation and torsades de pointes led several foreign bicalutamide manufacturers to state that use of bicalutamide and cisapride is contraindicated.<sup>1,2,3</sup> US and Canadian labeling recommend caution when bicalutamide is combined with any CYP3A4 substrate but don’t mention cisapride as a specific contraindication, likely due to its removal from US and Canadian markets.<sup>4,5</sup><br><br>The mechanism of this potential interaction is bicalutamide inhibition of CYP 3A4-mediated metabolism of cisapride.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Casodex</i> (bicalutamide) [summary of product characteristics]. Luton, Bedfordshire, England: AstraZeneca UK Limited; June 2012.</p>\n<p>2. <i>Cosudex</i> (bicalutamide) [summary of product characteristics]. North Ryde, New South Wales, Australia: AstraZeneca Pty Ltd; February 2010.</p>\n<p>3. <i>Casodex</i> (bicalutamide) [summary of product characteristics]. Plankstadt, Germany: Corden Pharma GmbH; June 2011.</p>\n<p>4. <i>Casodex</i> (bicalutamide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2010.</p>\n<p>5. <i>Casodex</i> (bicalutamide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8342":"<p><b>Title</b> Astemizole / Bicalutamide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bicalutamide may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of bicalutamide and astemizole due to increased risk of QTc prolongation and torsades de pointes. The combination of bicalutamide and astemizole is listed as a contraindication in the UK, Australian, and Singapore product labeling.</p> \n<p><b>Discussion</b> Given the ability of bicalutamide to inhibit CYP3A4, an enzyme responsible for the metabolism of astemizole, the resulting increased risk for QTc prolongation and torsades de pointes led several foreign bicalutamide manufacturers to state that use of bicalutamide and astemizole is contraindicated.<sup>1,2,3</sup> US and Canadian labeling recommend caution when bicalutamide is combined with any CYP3A4 substrate but don’t mention astemizole as a specific contraindication, likely due to its removal from US and Canadian markets.<sup>4,5</sup><br><br>The mechanism of this potential interaction is bicalutamide inhibition of CYP 3A4-mediated metabolism of astemizole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Casodex</i> (bicalutamide) [summary of product characteristics]. Luton, Bedfordshire, England: AstraZeneca UK Limited; June 2012.</p>\n<p>2. <i>Cosudex</i> (bicalutamide) [summary of product characteristics]. North Ryde, New South Wales, Australia: AstraZeneca Pty Ltd; February 2010.</p>\n<p>3. <i>Casodex</i> (bicalutamide) [summary of product characteristics]. Plankstadt, Germany: Corden Pharma GmbH; June 2011.</p>\n<p>4. <i>Casodex</i> (bicalutamide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2010.</p>\n<p>5. <i>Casodex</i> (bicalutamide) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8343":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Pholcodine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pholcodine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of pholcodine in combination with, or within 14 days of discontinuing, a monoamine oxidase inhibitor. U.K. product labeling specifically lists this combination as contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Pholcodine U.K. summaries of product characteristics list its use with or within 14 days after stopping a monoamine oxidase inhibitor (MAOI) as contraindicated.<sup>1,2</sup> While no published data characterizing an interaction between pholcodine and MAOIs are available, several reports describe signs and symptoms consistent with serotonin toxicity developing in patients treated with other opioid derivatives (including dextromethorphan) in combination with MAOIs.<sup>3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Covonia Dry Cough</i> (pholcodine) [UK summary of product characteristics]. Huddersfield, UK: Thornton &amp; Ross Ltd; March 2013.</p>\n<p>2. <i>Boots Dry Cough</i> (pholcodine) [UK summary of product characteristics]. Nottingham, UK: Thornton &amp; Ross Ltd; July 2013.</p>\n<p>3. Rivers N, Horner B. Possible lethal reaction between nardil and dextromethorphan. <i>Can Med Assoc J</i>. 1970;103(1):85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20311659\">[PubMed 20311659]</a></p>\n<p>4. Shamsie SJ, Barriga C. The hazards of use of monoamine oxidase inhibitors in disturbed adolescents. <i>Can Med Assoc J</i>. 1971;104(8):715. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5550381\">[PubMed 5550381]</a></p>\n<p>5. Sovner R, Wolfe J. Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. <i>N Engl J Med</i>. 1988;319(25):1671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3200285\">[PubMed 3200285]</a></p>\n<p>6. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. <i>Clin Pharmacol Ther</i>. 1993;53(1):84-88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8257462\">[PubMed 8257462]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8344":"<p><b>Title</b> Progestins (Contraceptive) / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients using ritonavir-boosted tipranavir should consider using an alternative or additional method of contraception. Injected depot medroxyprogesterone acetate is unlikely to participate in this interaction and may be used without need for additional contraception. When using levonorgestrel as an emergency contraceptive, recommendations outside of the United States suggest doubling the dose of levonorgestrel to 3 mg in women who have used enzyme inducing drugs in the previous 4 weeks.<sup>1</sup></p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> The norethindrone AUC was an average of 14% to 27% higher following administration of a single dose of ethinyl estradiol/norethindrone (0.035 mg/1 mg) to subjects who had been receiving tipranavir/ritonavir (500 mg/100 mg twice daily, n=21; or 750 mg/200 mg twice daily, n=13) for 21 days.<sup>2</sup> Though the exact clinical significance of these changes are uncertain, guidelines recommend that women taking tipranavir/ritonavir should use an alternative or additional methods of contraception, a recommendation that applies to both progestin-only oral contraceptives and etonorgestrel implants.<sup>3</sup> The guidelines do specifically note that injected depot medroxyprogesterone acetate does not appear to participate in this interaction and may be used without a need for additional contraception.<br><br>The mechanism of this interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. The Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. <i>Drug Safety Update</i>. 2016;10(2):1-8. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/553274/Sept_2016_DSU.pdf. Accessed September 28, 2016.</p>\n<p>2. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., April 2014.</p>\n<p>3. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Updated March 28, 2014. Accessed April 16, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8345":"<p><b>Title</b> Norethindrone / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Indinavir may increase the serum concentration of Norethindrone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The average AUC of norethindrone was 26% higher with concurrent indinavir in a study of 18 subjects who received ethinyl estradiol/norethindrone (0.035 mg/1 mg daily for 8 days) together with indinavir (800 mg three times/day for 8 days).<sup>1</sup> This change is not expected to be of clinical significance.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Crixivan</i> (indinavir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc., February 2012.</p>\n<p>2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed April 16, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8346":"<p><b>Title</b> Ethinyl Estradiol / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Indinavir may increase the serum concentration of Ethinyl Estradiol. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The average AUC of ethinyl estradiol was 22% higher with concurrent indinavir in a study of 18 subjects who received ethinyl estradiol/norethindrone (0.035 mg/1 mg daily for 8 days) together with indinavir (800 mg three times/day for 8 days).<sup>1</sup> This change is not expected to be of clinical significance.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Crixivan</i> (indinavir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc., February 2012.</p>\n<p>2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed April 16, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8347":"<p><b>Title</b> Apixaban / Agents with Antiplatelet Properties</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling states that concomitant use of prasugrel or ticagrelor is not recommended. Additionally, UK labeling lists the use of intravenous diclofenac in combination with anticoagulants as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. US and Canadian apixaban labeling recommend caution and increased monitoring if used with any antiplatelet agent. The Canadian product monograph for apixaban also specifically recommends avoiding concomitant use of prasugrel or ticagrelor.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Concomitant use of aspirin with apixaban has been shown to increase bleeding risk from 1.8% per year to 3.4% per year in patients with atrial fibrillation.<sup>1,2</sup> Apixaban combined with aspirin and/or clopidogrel was associated with an increased risk of major bleeding (1.3% versus 0.5%) for post-acute coronary syndrome (ACS) high-risk patients in a randomized control trial that was terminated early due to bleeding events.<sup>3</sup> In a phase 2 trial, doses above the approved maximum dose (10 mg/day) were associated with an increased risk of bleeding whereas therapeutic doses (i.e., 10 mg/day or less) showed only a non-significant increase in bleeding events.<sup>4</sup> Patients using dual antiplatelet therapy (clopidogrel and aspirin) together with apixaban had more bleeding events in the study. The use of these medications concomitantly is not contraindicated unless there is active bleeding,<sup>1</sup> but clinical benefit and risk should be assessed for each patient. The Canadian product monograph for apixaban also specifically recommends avoiding concomitant use of prasugrel or ticagrelor.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2015.</p>\n<p>2. Granger CB, Alexander JH, McMurrary JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOLE). <i>N Engl J Med</i>. 2011;365:981-992. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21870978\">[PubMed 21870978]</a></p>\n<p>3. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. <i>N Engl J Med</i>. 2011;365(8):699-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21780946\">[PubMed 21780946]</a></p>\n<p>4. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after actue coronary syndrome. <i>Circulation</i>. 2009;119(22):2877-2885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19470889\">[PubMed 19470889]</a></p>\n<p>5. Eliquis (apixaban) [product monograph]. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8348":"<p><b>Title</b> Tacrolimus (Systemic) / Clotrimazole (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clotrimazole (Topical) may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased tacrolimus concentrations and adjust dose as necessary when concomitantly administered with clotrimazole.</p> \n<p><b>Discussion</b> Although systemic concentrations of topically applied clotrimazole are reported to be negligible,<sup>1</sup> product labeling for topical clotrimazole in several countries warns of increased tacrolimus concentrations when tacrolimus is combined with clotrimazole.<sup>1,2,3</sup> US prescribing information does not mention this potential drug interaction.<sup>4</sup> <br><br>The clotrimazole oral buccal troche has been reported to increase tacrolimus serum concentrations. In a study of 35 allograft recipients in which 17 patients were given clotrimazole (10 mg oral troche three times daily x 7 days) and 18 patients were given nystatin (5 mL swish and swallow four times daily x 7 days), tacrolimus blood concentrations were an average of 135% to 250% higher with concurrent clotrimazole.<sup>5</sup> In another pharmacokinetic study, clotrimazole (10 mg oral troche three times daily x 5 days) was administered to 6 transplant patients on a stable tacrolimus dose. Mean tacrolimus AUC increased 250% and mean trough concentrations more than doubled with coadministration of clotrimazole.<sup>6</sup> Another report of 65 transplant recipients evaluated the effect of clotrimazole troche discontinuation on tacrolimus levels and rejection.<sup>7</sup> Overall, mean tacrolimus levels decreased 26%, but in patients who experienced an episode of rejection, the tacrolimus levels decreased 62%.<sup>7</sup> Two case reports also describe significant changes in tacrolimus serum concentrations when combined with clotrimazole.<sup>8,9</sup> There are no reports describing an interaction between tacrolimus and topical clotrimazole.<br><br>The likely mechanism of this interaction is inhibition of CYP3A by clotrimazole, resulting in reduced tacrolimus metabolism and increased serum concentrations. However, in vivo concentrations are unlikely to reach the stated inhibitory concentrations with standard use of topical clotrimazole in most patients.<sup>1</sup> This, along with the lack of studies involving concurrent use of topical clotrimazole and tacrolimus in patients, makes the clinical significance of this potential interaction unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Canesten</i> (clotrimazole) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; May 2011.</p>\n<p>2. <i>Canesten</i> (clotrimazole) [summary of product characteristics]. Strawberry Hill, Newbury, Berkshire; January 2014.</p>\n<p>3. <i> Canesten</i> (clotrimazole) [summary of product characteristics]. Leverkusen, Germany: Bayer Pharma AG; October 2013.</p>\n<p>4. <i>Gyne-Lotrimin</i> (clotrimazole) [prescribing information]. Memphis, TN: Schering-Plough; April 2010.</p>\n<p>5. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. <i>Clin Transplant</i>. 2001;15(2):95-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11264634\">[PubMed 11264634]</a></p>\n<p>6. Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. <i>Ther Drug Monit</i>. 2005;27(5):587-591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16175131\">[PubMed 16175131]</a></p>\n<p>7. Viesselmann CW, Descourouez JL, Jorgenson MR, Radke NA, Odorico JS. Clincally significant drug interaction between clotrimazole and tacrolimus in pancreas transplant recipients and associated risk of allograft rejection. <i>Pharmacotherapy</i>. 2016;36(3):335-341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26877191\">[PubMed 26877191]</a></p>\n<p>8. Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. <i>Transplantation</i>. 1991;52(6):1086-1087. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1721250\">[PubMed 1721250]</a> </p>\n<p>9. Choy M. Tacrolimus interaction with clotrimazole: a concise case report and literature review. <i>P T</i>. 2010;35(10):568-569. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21037909\">[PubMed 21037909]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8349":"<p><b>Title</b> Sirolimus / Clotrimazole (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clotrimazole (Topical) may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased sirolimus concentrations and adjust dose as necessary when concomitantly administered with clotrimazole.</p> \n<p><b>Discussion</b> Although systemic concentrations of topically applied clotrimazole are reported to be negligible,<sup>1</sup> product labeling for topical clotrimazole in several countries warns of increased tacrolimus and/or sirolimus concentrations when combined with clotrimazole.<sup>1,2,3</sup> US prescribing information does not mention this potential drug interaction.<sup>4</sup> <br><br>The clotrimazole oral buccal troche has been reported to increase tacrolimus serum concentrations. In a study of 35 allograft recipients in which 17 patients were given clotrimazole (10 mg oral troche TID x 7 days) and 18 patients were given nystatin (5 mL swish and swallow QID x 7 days), tacrolimus blood concentrations were an average of 135%-250% higher with concurrent clotrimazole.<sup>5</sup> In another pharmacokinetic study, clotrimazole (10 mg oral troche TID x 5 days) was administered to 6 transplant patients on a stable tacrolimus dose. Mean tacrolimus AUC increased 250% and mean trough concentrations more than doubled with coadministration of clotrimazole.<sup>6</sup> Two case reports also report significant changes in tacrolimus serum concentrations when combined with oral clotrimazole troches.<sup>7,8</sup> There are no reports describing an interaction between tacrolimus or sirolimus and topical clotrimazole.<br><br>The likely mechanism of this interaction is inhibition of CYP3A by clotrimazole, resulting in reduced sirolimus metabolism and increased serum concentrations. However, in vivo concentrations are unlikely to reach the stated inhibitory concentrations with standard use of topical clotrimazole in most patients.<sup>1,</sup> This, along with the lack of studies involving concurrent use of topical clotrimazole and sirolimus in patients, makes the clinical significance of this potential interaction unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Canesten</i> (clotrimazole) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; May 2011.</p>\n<p>2. <i>Canesten</i> (clotrimazole) [summary of product characteristics]. Strawberry Hill, Newbury, Berkshire; January 2014.</p>\n<p>3. <i> Canesten</i> (clotrimazole) [summary of product characteristics]. Leverkusen, Germany: Bayer Pharma AG; October 2013.</p>\n<p>4. <i>Gyne-Lotrimin</i> (clotrimazole) [prescribing information]. Memphis, TN: Schering-Plough; April 2010.</p>\n<p>5. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. <i>Clin Transplant</i>. 2001;15(2):95-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11264634\">[PubMed 11264634]</a></p>\n<p>6. Vasquez EM, Shin GP, Sifontis N, Benedetti E. Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. <i>Ther Drug Monit</i>. 2005;27(5):587-591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16175131\">[PubMed 16175131]</a></p>\n<p>7. Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. <i>Transplantation</i>. 1991;52(6):1086-1087. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1721250\">[PubMed 1721250]</a> </p>\n<p>8. Choy M. Tacrolimus interaction with clotrimazole. A concise case report and literature review. <i>P T</i>. 2010;35(10):568-569. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21037909\">[PubMed 21037909]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8350":"<p><b>Title</b> Thiopental / SulfiSOXAZOLE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> SulfiSOXAZOLE may enhance the therapeutic effect of Thiopental. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider thiopental dosing carefully when used together with sulfisoxazole as reduced thiopental doses may be required. Monitor patient response to treatment extra closely if using this combination. Repeat thiopental doses may also be required to maintain desired clinical effectiveness.</p> \n<p><b>Discussion</b> According to thiopental labeling, decreased thiopental doses may be required when used with sulfisoxazole.<sup>1,2</sup> Repeat thiopental doses may also be required to maintain desired clinical effectiveness.<br><br>The specific mechanism for this reported interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thiopental [summary of product characteristics]. Warriewood, New South Wales, Australia: Link Medical Products Pty Ltd., September 2013.</p>\n<p>2. Thiopental [summary of product characteristics]. Reading, Berkshire, United Kingdom: Archimedes Pharma UK Limited, January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8352":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / Siltuximab</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Siltuximab may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased levels/effects of CYP3A4 substrates (e.g., simvastatin) in patients receiving concurrent siltuximab therapy. Monitor for increased levels/effects of CYP3A4 substrates with siltuximab discontinuation.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzhydrocodone, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etizolam, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zolpidem, Zonisamide, Zopiclone</p>\n</div> \n<p><b>Discussion</b> Siltuximab binds to the cytokine interleukin-6 (IL-6) preventing it from binding to its receptors.<sup>1</sup> Currently, no in vitro or in vivo drug interaction studies have been conducted with siltuximab. However, in vitro, IL-6 decreased CYP3A4 mRNA by greater than 90%.<sup>2</sup> Inhibition of IL-6 signaling pathways by siltuximab may restore CYP3A4 activity in patients and thus increase the metabolism of CYP3A4 substrates. This effect may persist several weeks following discontinuation of therapy due to the long half-life of siltuximab.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sylvant</i> (siltuximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; April 2014.</p>\n<p>2. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6, and 3A4 mRNA levels in human hepatocytes. <i>Drug Metab Dispos</i>. 2007;35(9):1687-1693. [PubMed17576808]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8353":"<p><b>Title</b> Grass Pollen Allergen Extract (5 Grass Extract) / Beta-Blockers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian product labeling specifically lists this combination as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine. Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents. Canadian product labeling specifically lists this combination as contraindicated.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for grass pollen allergen extract (5 grass extract) lists its use in patients treated with beta-blockers as contraindicated, based on a potential for treatment with beta-blockers to inhibit epinephrine effects if epinephrine must be used to treat a severe allergic reaction to the extract.<sup>1</sup> U.S. labeling gives a less specific warning, stating that the pollen extract “may not be suitable” in patients receiving beta-blockers, with the same stated rationale.<sup>2</sup> <br><br>Beta-blockers are expected to antagonize beta adrenoceptor mediated effects of epinephrine, including beta-2 receptor mediated anti-anaphylactic effects.<sup>3</sup> Other epinephrine effects including vasoconstriction may be unaffected or even enhanced by beta-blockade. While some beta-blockers (e.g., metoprolol) are more beta-1 adrenoceptor selective, particularly at lower doses, U.S. and Canadian labeling makes no distinction between these and other beta-blockers.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Oralair</i> (grass pollen allergen extract [5 grass extract]) [product monograph]. Montreal, QC: Paladin Labs Inc; March 2012.</p>\n<p>2. <i>Oralair</i> (grass pollen allergen extract [5 grass extract]) [prescribing information]. Lenoir, NC: GREER Laboratories, Inc; April 2014.</p>\n<p>3. Warren JB, Pixley FJ, Dollery CT. Importance of beta 2-adrenoceptor stimulation in the suppression of intradermal antigen challenge by adrenaline. <i>Br J Clin Pharmacol</i>. 1989;27(2):173-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2565729\">[PubMed 2565729]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8354":"<p><b>Title</b> Grass Pollen Allergen Extract (5 Grass Extract) / Angiotensin-Converting Enzyme Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian product labeling specifically lists this combination as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to either grass pollen allergen extract (5 grass extract) or angiotensin-converting enzyme inhibitors in patients with indications for both agents. Canadian product labeling specifically lists this combination as contraindicated.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for grass pollen allergen extract (5 grass extract) lists its use in patients receiving angiotensin-converting enzyme (ACE) inhibitors as contraindicated, based on a theoretical potential for ACE inhibitors to increase the risk of serious allergic reaction to the extract.<sup>1</sup> The specific clinical risk and mechanism of this interaction have not been characterized. US labeling says nothing about this proposed interaction or its mechanism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Oralair</i> (grass pollen allergen extract [5 grass extract]) [product monograph]. Montreal, QC: Paladin Labs Inc; March 2012.</p>\n<p>2. <i>Oralair</i> (grass pollen allergen extract [5 grass extract]) [prescribing information]. Lenoir, NC: GREER Laboratories, Inc; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8355":"<p><b>Title</b> Thiopental / Aminophylline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminophylline may diminish the therapeutic effect of Thiopental. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for diminished clinical anesthetic response to thiopental in patients receiving aminophylline. Whether other methylxanthines, such as theophylline or caffeine, interact to a similar degree is unknown.</p> \n<p><b>Discussion</b> The depth and duration of thiopental anesthesia were both reduced by aminophylline in a study of 24 women who received anesthesia with intravenous (IV) thiopental 7 mg/kg and were given IV aminophylline 5.6 mg/kg.<sup>1</sup> In another study, sedation was greater at 5 minutes after aminophylline, but there was an approximately 15% decrease in the time spent in a post-anesthesia unit and reduced sedation at 20 minutes following administration of lower dose aminophylline (2 mg/kg) versus an equal volume of normal saline to women who underwent anesthesia with IV fentanyl (2 mcg/kg) and IV thiopental (4 mg/kg, with repeated 1 mg/kg doses as needed) in a study of 52 women.<sup>2</sup> A study in rats similarly found that aminophylline reduces thopental effects.<sup>3</sup><br><br>The specific mechanism of this apparent interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chen YC, Chan KH, Tsou MY, Wang H, Ho YY, Lee TY. The reversal effect of low dose aminophylline on thiopental-induced sedation. <i>Zhonghua Yi Xue Za Zhi (Taipei)</i>. 1993;52(3):145-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8252455\">[PubMed 8252455]</a></p>\n<p>2. Krintel JJ, Wegmann F. Aminophylline reduces the depth and duration of sedation with barbiturates. <i>Acta Anaesthesiol Scand</i>. 1987;31(4):352-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3296607\">[PubMed 3296607]</a></p>\n<p>3. Louie GL, Prokocimer PG, Nicholls EA, Maze M. Aminophylline shortens thiopental sleep-time and enhances noradrenergic neurotransmission in rats. <i>Brain Res</i>. 1986;383(1-2):377-381. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3021279\">[PubMed 3021279]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8356":"<p><b>Title</b> Thiopental / Antipsychotic Agents (Phenothiazines)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Thiopental. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient clinical status closely when using this combination. In particular, monitor for evidence of hypotension and/or exaggerated CNS effects.</p>\n<div>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> According to the thiopental summary of product characteristics, concurrent use of phenothiazines with thiopental can result in enhanced hypotensive effects and increased CNS excitatory effects.<sup>1</sup><br><br>Specific mechanism(s) for this apparent interaction is(are) unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thiopental [summary of product characteristics]. Warriewood, New South Wales, Australia: Link Medical Products Pty Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8357":"<p><b>Title</b> Acetohydroxamic Acid / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Acetohydroxamic Acid. Specifically, Alcohol (Ethyl) may increase the risk of Acetohydroxamic Acid associated rash. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients receiving acetohydroxamic acid that a transient flushing skin rash may develop shortly after alcohol consumption. Patients experiencing this should limit or stop alcohol consumption.</p> \n<p><b>Discussion</b> Acetohydroxamic acid US prescribing information states that several patients receiving the agent have experienced a flushing skin reaction, lasting approximately 30 minutes, following alcohol consumption.<sup>1</sup> The rash has been severe enough to warrant discontinuation in some cases, but most patients were able to continue treatment with more limited alcohol intake.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lithostat</i> (acetohydroxamic acid) [prescribing information]. San Antonio, TX: Mission Pharmaceutical Company; May 2000.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8358":"<p><b>Title</b> Tetanus Toxoids Vaccines / Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine may diminish the therapeutic effect of Tetanus Toxoids Vaccines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible, administer the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine.</p>\n<div>\n <p><b>Tetanus Toxoids Vaccines Interacting Members</b> Diphtheria and Tetanus Toxoids, Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated), and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine, Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), and Poliovirus (Inactivated) Vaccine, Tetanus Toxoid (Adsorbed)</p>\n</div> \n<p><b>Discussion</b> According to the product monograph for the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine, administration one month after administration of a DTPa-HBV-IPV/Hib vaccine was associated with a reduced immune response to the meningococcal vaccine (i.e., reduced MenA, MenC, and MenW-135 rSBA geometric mean titres).<sup>1</sup> More than 99% of recipients still had titres of at least 8, indicating a sufficient immune response, so the clinical significance of this potential interaction is uncertain. However, the product monograph recommends administering the meningococcal polysaccharide (groups A / C / Y and W-135) tetanus toxoid conjugate vaccine either together with or at least one month before a tetanus toxoids-containing vaccine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Nimenrix</i> (meningococcal polysaccharide groups A, C, W-135, and Y conjugate vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc., March 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8377":"<p><b>Title</b> TraZODone / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of TraZODone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider using a lower dose of trazodone when used in combination with ritonavir. Monitor for increased effects and toxicity of trazodone if ritonavir is initiated/dose increased, and for decreased effects if ritonavir is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Peak serum trazodone concentrations (50 mg single dose) were increased approximately 34% in 10 healthy subjects when administered concurrently with ritonavir (200 mg for 4 doses).<sup>1</sup> The half-life of trazodone increased approximately 2-fold. Increased side effects were noted, including sedation, fatigue, and performance impairment. Hypotension and syncope were also reported in the treatment group.<br><br>The suspected mechanism of this interaction is protease inhibitor-mediated inhibition of the CYP3A enzyme responsible for trazodone metabolism.<sup>1,2</sup> An in vitro study in human liver microsomes found that both ritonavir and indinavir were potent inhibitors of trazodone metabolism.<sup>2</sup> Saquinavir and nelfinavir were weaker inhibitors of trazodone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. <i>J Clin Pharmacol</i>. 2003;43(4):414-422. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12723462\">[PubMed 12723462]</a></p>\n<p>2. Zalma A, von Moltke LL, Granda BW, et al. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. <i>Biol Psychiatry</i>. 2000;47(7):655-661. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10745059\">[PubMed 10745059]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8378":"<p><b>Title</b> Digoxin / Epoprostenol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Epoprostenol may increase the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Though the magnitude of this interaction is of unlikely clinical significance for most patients, the interaction may be significant for those patients with other risk factors for toxicity (e.g., electrolyte abnormalities, renal dysfunction, other interacting drugs, etc.). Monitor patient response to digoxin more closely following initiation or cessation of concurrent epoprostenol.</p> \n<p><b>Discussion</b> Digoxin apparent oral clearance was 15% lower within two days of epoprostenol initiation in patients with heart failure (n=30) also receiving digoxin.<sup>1</sup> By day 87, digoxin oral clearance had returned to baseline; no adverse events or necessary digoxin dose adjustments were noted. Both the mechanism and clinical significance of this possible interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Flolan</i> (epoprostenol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8379":"<p><b>Title</b> Tacrolimus (Systemic) / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only anticipated with tacrolimus extended-release products (Astagraf XL and Envarsus XR brands).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase the absorption of Tacrolimus (Systemic). More specifically, the initial absorption rate may be increased, as alcohol may speed the release of tacrolimus from extended-release tablets. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients receiving extended-release tacrolimus products (Astagraf XL or Envarsus XR) not to take the medication with alcoholic beverages.</p> \n<p><b>Discussion</b> Tacrolimus US prescribing information warns that alcohol may increase the rate of its release from extended-release products.<sup>1,2</sup> Due to the potential for altered absorption of the drug, administration with an alcoholic beverage is not recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Astagraf XL (tacrolimus) extended-release capsules [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; December 2015.</p>\n<p>2. Envarsus XR (tacrolimus) extended-release tablets [prescribing information]. Edison, NJ: Veloxis Pharmaceuticals Inc.; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8380":"<p><b>Title</b> Ioflupane I 123 / Amoxapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amoxapine may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of amoxapine in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of amoxapine prior to ioflupane administration will minimize the interference is unknown.</p> \n<p><b>Discussion</b> According to ioflupane prescribing information, ioflupane binds to the dopamine transporter.<sup>1</sup> Amoxapine binds with high affinity to the dopamine transporter and may interfere with the image obtained following administration of ioflupane.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>DaTscan</i> (ioflupane I 123) [prescribing information]. Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc.; April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8381":"<p><b>Title</b> Ioflupane I 123 / Phenylephrine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of phenylephrine in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of phenylephrine prior to ioflupane administration may minimize the interference is unknown.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> As summarized in a review on the topic, high plasma levels of phenylephrine and norepinephrine may change the affinity of radiotracers for DATs.<sup>2</sup> Further studies are needed to determine if adrenergic agonists given at clinical doses affect DAT imaging.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8382":"<p><b>Title</b> Tacrolimus (Systemic) / Magnesium Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with oral tacrolimus administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Magnesium Hydroxide may increase the serum concentration of Tacrolimus (Systemic). Magnesium Hydroxide may decrease the serum concentration of Tacrolimus (Systemic). Specifically, maximum concentration may decrease. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In vitro studies in simulated gastric fluids suggested a potential for pH dependent degradation of tacrolimus in the presence of antacids, as well as potential adsorption of tacrolimus by aluminum.<sup>1</sup> However, tacrolimus prescribing information describes a study of healthy volunteers in which coadministration of aluminum/magnesium hydroxide decreased maximum tacrolimus concentration by 10% but increased AUC by 21%.<sup>2</sup> The pharmacokinetic impact of any adsorption and/or degradation effects in the presence of these antacids in vivo therefore appears to be minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Steeves M, Abdallah HY, Venkataramanan R, et al, “In-Vitro Interaction of a Novel Immunosuppressant, FK 506, and Antacids,” <i>J Pharm Pharmacol</i>, 1991, 43(8):574-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1717676\">[PubMed 1717676]</a></p>\n<p>2. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8383":"<p><b>Title</b> Bazedoxifene / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased effects/lack of efficacy of bazedoxifene if taken concomitantly with phenytoin. If bazedoxifene is being taken with estrogen therapy (eg, as part of the conjugated estrogen/bazedoxifene combination product [Duavee]) and taken concomitantly with phenytoin, patients may be at an increased risk for endometrial hyperplasia and should undergo increased monitoring.</p> \n<p><b>Discussion</b> Bazedoxifene is not metabolized by cytochrome P450 enzymes to any significant extent. Rather, its major route of metabolism occurs via glucuronidation in the liver (UGT1A1) and the intestinal wall (UGT1A8 and UGT1A10).<sup>1,2</sup> Product labeling cautions that concomitant use of bazedoxifene with UGT inducers, such as phenytoin, could result in lower systemic exposure. This lower systemic exposure may attenuate the protection against endometrial hyperplasia conferred by bazedoxifene when it is coadministered with estrogen,<sup>3</sup> or result in decreased efficacy in the treatment of osteoporosis when used as a single agent.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lusin TT, Tomasic T, Trontelj J, Mrhar A, Peterlin-Masic L. In vitro bioactivation of bazedoxifene and 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol in human liver microsomes. <i>Chem Biol Interact</i>. 2012;197(1):8-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22429462\">[PubMed 22429462]</a></p>\n<p>2. Shen L, Ahmad S, Park S, et al. In vitro metabolism, permeability, and efflux of bazedoxifene in humans. <i>Drug Metab Dispos</i>. 2010;38(9):1471-1479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20516255\">[PubMed 20516255]</a></p>\n<p>3. <i>Duavee</i> (conjugated estrogens/bazedoxifene) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; October 2013.</p>\n<p>4. <i>Conbriza</i> (bazedoxifene) [summary of product characteristics]. Sandwich, Kent, United Kingdom: Pfizer Limited; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8385":"<p><b>Title</b> Androgens / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased edema if androgens are combined with systemic corticosteroids. Particular caution should be exercised in patients with cardiac, renal, or hepatic disease.</p>\n<div>\n <p><b>Androgens Interacting Members</b> Danazol, Fluoxymesterone, Mesterolone, MethylTESTOSTERone, Nandrolone, Oxandrolone, Oxymetholone, Testosterone</p>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for testosterone and several other androgens warns of the increased risk of edema when androgens are combined with systemic corticosteroids.<sup>1,2,3,4,5</sup> Both classes of medications can increase edema formation and thus the combination is expected to increase this risk. The clinical significance of this edema is likely to be greater in patients with preexisting cardiac, renal, or hepatic disease.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Testosterone gel [prescribing information]. Allegan, MI: Perrigo-Israel Pharmaceuticals Ltd; January 2013.</p>\n<p>2. <i>Androxy</i> (fluoxymesterone) [prescribing information]. Minneapolis, MN: Upsher-Smith Laboratories Inc; May 2004.</p>\n<p>3. <i>Anadrol</i> (oxymetholone) [prescribing information]. Marietta, GA: Unimed Pharmaceuticals Inc; August 2004. </p>\n<p>4. <i>Deca Durabolin</i> (nandrolone) [summary of product characteristics]. Milton Road, Cambridge, England: Organon Laboratories Limited; February 2012. </p>\n<p>5. Oxandrolone [prescribing information]. Minneapolis, MN: Upsher-Smith Laboratories Inc; November 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8390":"<p><b>Title</b> Cyanocobalamin / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase the serum concentration of Cyanocobalamin. Alcohol (Ethyl) may also decrease or have no effect on Cyanocobalamin serum concentrations under some circumstances; clinical data are inconsistent. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 4 chronic alcoholic patients with normal liver biopsies, renal excretion of radiolabeled cyanocobalamin following an oral dose (0.75 mcg, given with intrinsic factor concentrate) was on average 35%-42% lower during periods of heavy alcohol consumption (maximum consumption of 158 to 253 g/day for 3-8 weeks, substituted isocalorically for other dietary carbohydrates).<sup>1</sup> A few additional experimental and observational reports, including a follow-up report by the same group after enrollment of 4 additional patients, support a decrease in vitamin B12 absorption, decrease in blood vitamin B12 concentrations, or greater likelihood of vitamin B12 deficiency in chronic alcoholic patients.<sup>2,3,4,5</sup> In contrast, several other reports suggest normal or even elevated serum vitamin B12 concentrations (elevations particularly among women in one report) in alcoholic patients.<sup>6,7,8,9,10</sup> Studies of nonalcoholic patients suggest anywhere from a minor (5%) decrease to a substantial increase in vitamin B12 concentrations with moderate alcohol consumption.<sup>11,12,13,14</sup><br><br>The mechanism of any interaction between vitamin B12 and alcohol is not clear. In one of the above studies, vitamin B12 binding to intrinsic factor was greatly reduced in gastric fluid of alcoholic patients despite apparently normal intrinsic factor secretion.<sup>5</sup> Dietary deficiencies could also contribute to low serum vitamin B12 concentrations in some patients. However, serum vitamin B12 concentrations appear to correlate positively rather than negatively with markers of hepatocellular damage in alcoholic patients.<sup>15,16</sup> While the mechanism of this is not clear, it suggests some potential compensation for reductions in intake or absorption. Further complicating this issue, particularly the interpretation of the clinical studies summarized above, additional data indicate that megaloblastic anemia in alcoholic patients may respond to vitamin B12 supplementation even when serum concentrations are normal.<sup>17</sup> Thus in some instances there may be a functional vitamin B12 deficiency in alcoholic patients that cannot be reliably assessed with standard serum concentration assays.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lindenbaum J, Lieber CS. Alcohol-induced malabsorption of vitamin B12 in man. <i>Nature</i>. 1969;224(5221):806. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5361658\">[PubMed 5361658]</a></p>\n<p>2. Roggin GM, Iber FL, Kater RM, Tabon F. Malabsorption in the chronic alcoholic. <i>Johns Hopkins Med J</i>. 1969;125(6):321-330. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5370736\">[PubMed 5370736]</a></p>\n<p>3. Mahmud K, Ripley D, Doscherholmen A. Vitamin B 12 absorption tests. Their unreliability in postgastrectomy states. <i>JAMA</i>. 1971;216(7):1167-1171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4930579\">[PubMed 4930579]</a></p>\n<p>4. Lindenbaum J, Lieber CS. Effects of chronic ethanol administration on intestinal absorption in man in the absence of nutritional deficiency. <i>Ann N Y Acad Sci</i>. 1975;252:228-234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1056726\">[PubMed 1056726]</a></p>\n<p>5. Marotta F, Tajiri H, Barreto R, et al. Cyanocobalamin absorption abnormality in alcoholics is improved by oral supplementation with a fermented papaya-derived antioxidant. <i>Hepatogastroenterology</i>. 2000;47(34):1189-1194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11020912\">[PubMed 11020912]</a></p>\n<p>6. Goldman PA, Jankowski CB, Drum DE. A sex difference in the serum vitamin B-12 levels of hospitalized alcoholics. <i>Curr Alcohol</i>. 1979;5:237-249. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=39708\">[PubMed 39708]</a></p>\n<p>7. Gimsing P, Melgaard B, Andersen K, Vilstrup H, Hippe E. Vitamin B-12 and folate function in chronic alcoholic men with peripheral neuropathy and encephalopathy. <i>J Nutr</i>. 1989;119(3):416-424. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2537891\">[PubMed 2537891]</a></p>\n<p>8. Carney MW, Sheffield B. Serum folate and B12 and haematological status of in-patient alcoholics. <i>Br J Addict Alcohol Other Drugs</i>. 1978;73(1):3-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=272902\">[PubMed 272902]</a></p>\n<p>9. Myrhed M, Berglund L, Bottiger LE. Alcohol consumption and hematology. <i>Acta Med Scand</i>. 1977;202(1-6):11-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=899873\">[PubMed 899873]</a></p>\n<p>10. Gloria L, Cravo M, Camilo ME, et al. Nutritional deficiencies in chronic alcoholics: relation to dietary intake and alcohol consumption. <i>Am J Gastroenterol</i>. 1997;92(3):485-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9068475\">[PubMed 9068475]</a></p>\n<p>11. Mayer O Jr, Simon J, Rosolova H. A population study of the influence of beer consumption on folate and homocysteine concentrations. <i>Eur J Clin Nutr</i>. 2001;55(7):605-609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11464234\">[PubMed 11464234]</a></p>\n<p>12. Laufer EM, Hartman TJ, Baer DJ, et al. Effects of moderate alcohol consumption on folate and vitamin B(12) status in postmenopausal women. <i>Eur J Clin Nutr</i>. 2004;58(11):1518-1524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15138463\">[PubMed 15138463]</a></p>\n<p>13. Hin H, Clarke R, Sherliker P, et al. Clinical relevance of low serum vitamin B12 concentrations in older people: the Banbury B12 study. <i>Age Ageing</i>. 2006;35(4):416-422. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16709605\">[PubMed 16709605]</a></p>\n<p>14. Varghese AI, Varughese GI. Low serum vitamin B12 in older people: the role of alcohol and thyroid status. <i>Age Ageing</i>. 2007;36(2):231-232. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17234625\">[PubMed 17234625]</a></p>\n<p>15. Himmerich H, Anghelescu I, Klawe C, Szegedi A. Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients. <i>Alcohol Alcohol</i>. 2001;36(1):26-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11139412\">[PubMed 11139412]</a></p>\n<p>16. Lambert D, Benhayoun S, Adjalla C, et al. Alcoholic cirrhosis and cobalamin metabolism. <i>Digestion</i>. 1997;58(1):64-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9018012\">[PubMed 9018012]</a></p>\n<p>17. Fragasso A, Mannarella C, Ciancio A, Sacco A. Functional vitamin B12 deficiency in alcoholics: an intriguing finding in a retrospective study of megaloblastic anemic patients. <i>Eur J Intern Med</i>. 2010;21(2):97-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20206879\">[PubMed 20206879]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8391":"<p><b>Title</b> Ceritinib / Corticosteroids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving this combination should be monitored closely for evidence of severe hyperglycemia (serum glucose greater than 250 mg/dL). Patients with a history of diabetes or glucose intolerance are likely at a substantially increased risk. Initiation or adjustment of anti-hyperglycemic medications may be necessary.</p>\n<div>\n <p><b>Corticosteroids Interacting Members</b> Alclometasone, Amcinonide, Beclomethasone (Nasal), Beclomethasone (Oral Inhalation), Beclomethasone (Topical), Betamethasone (Nasal), Betamethasone (Ophthalmic), Betamethasone (Systemic), Betamethasone (Topical), Budesonide (Nasal), Budesonide (Oral Inhalation), Budesonide (Systemic), Budesonide (Topical), Ciclesonide (Nasal), Ciclesonide (Oral Inhalation), Clobetasol, Clobetasone, Clocortolone, Corticotropin, Cortisone, Deflazacort, Desonide, Desoximetasone, Dexamethasone (Ophthalmic), Dexamethasone (Systemic), Diflorasone, Diflucortolone, Difluprednate, Fludrocortisone, Flunisolide (Nasal), Flunisolide (Oral Inhalation), Fluocinolone (Ophthalmic), Fluocinolone (Topical), Fluocinonide, Fluorometholone, Flurandrenolide, Fluticasone (Nasal), Fluticasone (Oral Inhalation), Fluticasone (Topical), Halcinonide, Halobetasol, Hydrocortisone (Systemic), Hydrocortisone (Topical), Loteprednol, Medrysone, MethylPREDNISolone, Mometasone (Nasal), Mometasone (Oral Inhalation), Mometasone (Topical), Prednicarbate, PrednisoLONE (Ophthalmic), PrednisoLONE (Systemic), PrednisoLONE (Topical), PredniSONE, Rimexolone, Tixocortol Pivalate, Triamcinolone (Nasal), Triamcinolone (Ophthalmic), Triamcinolone (Systemic), Triamcinolone (Topical)<br><b>Exception</b> Hydrocortisone (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> According to the ceritinib prescribing information, concurrent use of corticosteroids was associated with a 2-fold increase in the risk for serious hyperglycemia (serum glucose greater than 250 mg/dL).<sup>1</sup> Serious hyperglycemia was reported in 13% of patients taking ceritinib in one clinical trial, with patients with diabetes/glucose intolerance and those on corticosteroids at greater risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zykadia</i> (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8392":"<p><b>Title</b> Ceritinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of strong CYP3A4 inducers with ceritinib.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The average ceritinib AUC was deceased by 70% when given to healthy volunteers (n=19) who had received the strong CYP3A4 inducer rifampin (600 mg daily for 14 days).<sup>1</sup><br><br>The specific mechanism for this apparent interaction appears to be increased CYP3A-mediated ceritinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zykadia</i> (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8393":"<p><b>Title</b> Ceritinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of strong CYP3A4 inhibitors with ceritinib when possible. If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest 150 mg). After the strong CYP3A4 inhibitor is discontinued the prior ceritinib dose should be resumed.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The average ceritinib AUC was increased by 2.9-fold when given to healthy volunteers (n=19) who had received the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily for 14 days).<sup>1</sup><br><br>The specific mechanism for this apparent interaction appears to be inhibition of the CYP3A-mediated ceritinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zykadia</i> (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8394":"<p><b>Title</b> Ceritinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Ceritinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of strong CYP3A4 inducers, such as St Johns wort, with ceritinib.</p> \n<p><b>Discussion</b> The average ceritinib AUC was deceased by 70% when given to healthy volunteers (n=19) who had received the strong CYP3A4 inducer rifampin (600 mg daily for 14 days).<sup>1</sup> As a result, the ceritinib prescribing information recommends avoiding concurrent use with strong CYP3A4 inducers such as St Johns wort.<br><br>The specific mechanism for this apparent interaction appears to be increased CYP3A-mediated ceritinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zykadia</i> (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8395":"<p><b>Title</b> Ceritinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Ceritinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Do not consume grapefruit or grapefruit juice with ceritinib.</p> \n<p><b>Discussion</b> The average ceritinib AUC was increased by 2.9-fold when given to healthy volunteers (n=19) who had received the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily for 14 days).<sup>1</sup> Grapefruit and grapefruit juice are generally considered moderate CYP3A inhibitors, but the ceritinib prescribing information recommends avoiding use of grapefruit or grapefruit juice. It is also important to note that the the significance of grapefruit's CYP3A inhibition may vary according to both the amount and specific variety of grapefruit consumed.<br><br>The specific mechanism for this apparent interaction appears to be primarily inhibition of the CYP3A-mediated ceritinib metabolism, though grapefruit juice may also inhibit the p-glycoprotein-mediated transport of ceritinib.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zykadia</i> (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8396":"<p><b>Title</b> Aminophylline / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase the serum concentration of Aminophylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider additional monitoring of theophylline concentrations in patients who consume alcohol, particularly when alcohol consumption patterns change.</p> \n<p><b>Discussion</b> In a clinical study summarized in theophylline U.S. prescribing information, consumption of alcohol (3 mL/kg whiskey, containing 0.95 g/kg alcohol) between 9 PM and 11 PM increased the AUC of a single oral dose of immediate-release theophylline (5 mg/kg) given at 9 AM the next day by roughly 25%.<sup>1,2</sup> The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thompson PJ. Social nocturnal alcohol consumption and pharmacokinetics of theophylline. <i>Chest</i>. 1992;101(1):156-159. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1729062\">[PubMed 1729062]</a></p>\n<p>2. <i>Theo-24</i> (theophylline) [prescribing information]. Smyrna, GA: UCB Pharma, Inc; December 2001.</p>\n<p>3. <i>Theolair</i> (theophylline) [prescribing information]. Northridge, CA: 3M Pharmaceuticals; September 1996.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8397":"<p><b>Title</b> Theophylline / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase the serum concentration of Theophylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider additional monitoring of theophylline concentrations in patients who consume alcohol, particularly when alcohol consumption patterns change.</p> \n<p><b>Discussion</b> In a clinical study summarized in theophylline U.S. prescribing information, consumption of alcohol (3 mL/kg whiskey, containing 0.95 g/kg alcohol) between 9 PM and 11 PM increased the AUC of a single oral dose of immediate-release theophylline (5 mg/kg) given at 9 AM the next day by roughly 25%.<sup>1,2</sup> The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thompson PJ. Social nocturnal alcohol consumption and pharmacokinetics of theophylline. <i>Chest</i>. 1992;101(1):156-159. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1729062\">[PubMed 1729062]</a></p>\n<p>2. <i>Theo-24</i> (theophylline) [prescribing information]. Smyrna, GA: UCB Pharma, Inc; December 2001.</p>\n<p>3. <i>Theolair</i> (theophylline) [prescribing information]. Northridge, CA: 3M Pharmaceuticals; September 1996.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8398":"<p><b>Title</b> Alcohol (Ethyl) / Cisapride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cisapride may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, Alcohol (Ethyl) sedative and psychomotor effects may be enhanced. Alcohol (Ethyl) may also worsen nocturnal heartburn. Cisapride may increase the serum concentration of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients receiving cisapride that sedative and psychomotor effects of alcohol may be enhanced by cisapride. Alcohol may also worsen nocturnal heartburn.</p> \n<p><b>Discussion</b> Cisapride US prescribing information warns that although the agent does not cause sedation nor impact psychomotor function when used alone, it may enhance the sedative effects of alcohol.<sup>1</sup> The mechanism of this possible interaction is not clear. Cisapride induced increases in gastric emptying rate could increase peak ethanol blood concentrations, although in two clinical studies of healthy volunteers this effect was small (14%-47%) and inconsistent.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Propulsid</i> (cisapride) [prescribing information]. Titusville, NJ: Janssen Pharmaceutica; January 2000.</p>\n<p>2. Dziekan G, Contesse J, Werth B, Schwarzer G, Reinhart WH. Cisapride increases peak plasma and saliva ethanol levels under fasting conditions. <i>J Intern Med</i>. 1997;242(6):479-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9437408\">[PubMed 9437408]</a></p>\n<p>3. Kechagias S, Jonsson KA, Jones AW. Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. <i>Br J Clin Pharmacol</i>. 1999;48(5):728-732. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594475\">[PubMed 10594475]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8399":"<p><b>Title</b> Cyproterone / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Patients receiving cyproterone for hypersexuality should avoid alcohol consumption.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may diminish the therapeutic effect of Cyproterone. More specifically, alcohol may interfere with antiandrogenic effects of Cyproterone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for diminished antiandrogenic effects of cyproterone in patients who consume alcohol. Advise patients receiving cyproterone for hypersexuality to avoid alcohol during treatment.</p> \n<p><b>Discussion</b> The cyproterone Canadian product monograph states that alcohol may reduce the agent's antiandrogenic effects in hypersexuality.<sup>1</sup> Consequently, alcohol consumption is not recommended during cyproterone treatment for that indication. <br><br>A single published case report also describes a 31 year old woman who begain experiencing symptoms of alcohol intolterance including facial flush, sweating, palpitations, nausea, vomiting, and diarrhea shortly after initiating a cyproterone-containing oral contraceptive.<sup>2</sup> However, the mechanism of this interaction is unclear and there is no additional published support for this kind of reaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Riva-cyproterone</i> (cyproterone) [product monograph]. Blainville, QC: Laboratoire Riva Inc; October 2012.</p>\n<p>2. Nitzan Z, Dan M. Disulfiram-like effect of cyproterone acetate. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2009;146(2):236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18155349\">[PubMed 18155349]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}